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ABBREVIATIONS 
 
agr accessory gene regulator 
AIP autoinducing peptide  
asp23 alkaline-shock protein 23  
CA-MRSA community-acquired MRSA 
ccrA cassette chromosome recombinases A  
ccrB cassette chromosome recombinases B 
ClfA clumping factor A  
ClfB clumping factor B  
cna collagen binding protein  
CPX ciprofloxacin  
DIG digoxigenin  
ECM extracellular matrix  
Ebp elastin-binding protein 
EFT exfoliative toxins 
Fn fibronectin  
fnbA fibronectin binding gene A 
fnbB fibronectin binding gene B 
FnBPA fibronectin-binding proteins A 
FnBPB fibronectin-binding Protein B 
GI genomic islands  
HA-MRSA hospital-acquired MRSA  
HCWs healthcare workers 
hla alpha-hemolysin gene 
IgG immunoglobulin G  
IS insertion sequence  
MDR multidrug resistance  
mec methicillin resistant gene 
MHB mueller-hinton broth  
MICs minimum inhibitory concentrations  
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MRSA methicillin resistant Staphylococcus aureus  
MSCRAMM microbial surface components recognizing adhesive 
matrix molecules 
NNIS the National Nosocomial Infections Surveillance 
system  
ORF open reading frames  
PBP penicillin binding protein  
PBS phosphate-buffered saline 
PFGE pulsed-field gel electrophoresis  
PMMA polymethylmethacrylate 
Q-R quinolone resistant  
QRDR quinolone resistance-determining region 
RGD arginine-glycine-aspartate 
rsb regulators of Sigma B  
sar staphylococcal accessory regulator  
SCCmec staphylococcal cassette chromosome mec 
SE staphylococcal enterotoxin 
SigB transcription factor Sigma B  
spa protein A  
TCS two-component system  
TSST toxic shock syndrome toxin 
VISA vancomycin-intermediate S. aureus  
VRSA vancomycin-resistant S. aureus  
σA primary sigma factor 
σB alternative sigma factor B 
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Résumé du travail en français 
 
Les souches nosocomiales de Staphylococcus aureus (nom commun: staphylocoque doré) 
représentent la source majeure des infections hospitalières. Bien que munies d’un vaste arsenal 
de facteurs de virulence, les souches de S. aureus ne créent pas systématiquement des infections 
mais colonisent le plus souvent les muqueuses d’un grand nombre de porteurs sains. De plus, le 
spectre d’infections causées par S. aureus est très étendu, allant des infections cutanées mineures 
jusqu’à des infections systémiques sévères telles que septicémies et endocardites. Ces 
caractéristiques de virulence font de S. aureus un pathogène majeur d’infections hospitalières et 
communautaires. En milieu hospitalier, la forte pression sélective des antibiotiques depuis un 
demi-siècle a généré une augmentation croissante de résistances multiples à différentes 
catégories d’antibiotiques. Des observations récentes montrent également une augmentation 
croissante de la résistance à un ou plusieurs antibiotiques chez les souches de S. aureus 
responsables d’infections communautaires.  
Parmi les différentes catégories de résistance antibiotique, celle ayant l’impact nosocomial 
le plus important est la résistance à la méticilline (et à l’ensemble des autres béta-lactamines et 
céphalosporines). Les souches de S. aureus résistantes à la méticilline, connues sous l’acronyme 
de MRSA, font l’objet d’une surveillance épidémiologique constante dans la plupart des 
hôpitaux du monde entier. Bien qu’une proportion importante des souches de MRSA colonisent 
de façon asymptomatique les muqueuses nasales des patients hospitalisés, elles sont à l’origine 
d’une forte proportion d’infections nosocomiales chez ces même patients. Une caractéristique 
importante des souches MRSA est d’associer la résistance à la méticilline avec celle à d’autres 
catégories d’antibiotiques (macrolides, aminosides, fluoroquinolones). Moins fréquemment, on 
observe chez les souches MRSA des co-résistances à la rifampicine, au co-trimoxazol, ou à des 
glycopeptides tels que la teicoplanine ou la vancomycine. La forte pression sélective des 
antibiotiques ainsi que l’augmentation croissante de résistances multiples à différentes catégories 
d’antibiotiques ont forcément un impact sur les caractéristiques de virulence et l’évolution des 
souches MRSA nosocomiales de S. aureus les plus adaptées au milieu hospitalier. L’éradication 
des souches MRSA nosocomiales est un objectif difficile à atteindre, car les méthodes de 
décolonisation des porteurs asymptomatiques sont peu efficaces à long terme. 
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En plus des antibiotiques et antiseptiques locaux auxquels ils sont exposés, les isolats 
nosocomiaux de S. aureus (incl. MRSA) doivent également affronter d’autres stress physiques 
ou chimiques, tels que les hautes températures, les rayons UV, les traitements alcooliques,  etc. 
Les souches de S. aureus (incl. MRSA) ont développé au cours de leur évolution des systèmes 
efficaces de réponses coordonnées à ces différents stress, qui favorisent leur survie dans un 
environnement hospitalier particulièrement hostile. Parmi ces réponses coordonnées aux agents 
de stress, certaines leur permettent de réparer leur ADN endommagé alors que d’autres vont 
réparer les protéines endommagées ou dénaturées. Ces différents systèmes de réparation sont mal 
connus car ils ont été très peu étudiés chez les souches de S. aureus. Cependant, nous pouvons 
modéliser en partie leur fonctionnement grâce à des systèmes homologues étudiés en détail chez 
d’autres bactéries à Gram positif (Bacillus subtilis) ou Gram négatif (Escherichia coli). Nous 
pouvons également prédire leur présence grâce aux séquençages complets des génomes de 
plusieurs souches de S. aureus. 
Deux systèmes permettant de réparer chez S. aureus les lésions de l’ADN (système SOS) 
ou de répondre à divers stress physico-chimiques (par l’intermédiaire du facteur de transcription 
alternatif Sigma B) ont été particulièrement étudiés dans mon laboratoire d’accueil. Le système 
SOS de réparation de l’ADN est principalement stimulé par l’exposition à des fluoroquinolones 
(ex. norfloxacine, ciprofloxacine, levofloxacine, moxifloxacine, etc.) ou par d’autres types de 
lésions de l’ADN par rayons UV ou certains agents chimiques (ex. mitomycine). Les 
fluoroquinolones sont utilisées très intensivement depuis une quinzaine d’années en milieu 
hospitalier et ambulatoire et la majorité des souches MRSA sont devenues hautement résistantes 
à cette classe d’antibiotiques. Le système SOS a surtout été étudié en détail chez E. coli et 
beaucoup moins chez les bactéries à Gram positif telles que B. subtilis ou S. aureus. Les 
homologies entre espèces bactériennes ne sont que partielles. Toutefois, la partie la plus centrale 
du système SOS, qui est commune à la quasi-totalité des espèces bactériennes étudiées, est le 
système RecA-LexA. La protéine LexA est le répresseur principal de l’ensemble des gènes du 
système SOS, qui ne sont presque pas exprimés à l’état de repos. A l’inverse, la protéine RecA, 
qui s’auto-active au contact de lésions de l’ADN, induit un clivage spontané de la protéine LexA 
permettant la transcription des gènes SOS précédemment réprimés par LexA. 
Le système sigma B de réponse globale aux stress a comme élément central une sous-unité 
de l’ARN polymérase qui reconnaît spécifiquement certains gènes dont la transcription est 
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déclenchée par exposition à certains stress. Dans cette situation, la sous-unité sigma B va 
remplacer la sous-unité sigma A de l’ARN polymérase pour permettre l’expression de gènes de 
réponses aux stress. La reconnaissance des gènes induits par le stress se fait grâce à des 
changements de courtes séquences nucléotidiques des régions promotrices –35 et –10, en amont 
des codons initiateurs de la transcription, qui sont spécifiquement reconnues par la sous-unité 
sigma B associée à l’ARN polymérase. La synthèse et l’activité de la sous-unité sigma B sont 
contrôlées par un opéron associant le gène codant pour cette protéine avec trois autres gènes 
synthétisant des régulateurs contrôlant de manière stricte la concentration intracytoplasmique de 
Sigma B. Ces trois régulateurs de Sigma B sont RsbW (formant un complexe avec sigma B dans 
les conditions de repos), RsbV (inactif dans les conditions de repos, mais activé par le stress et 
menant à la libération de Sigma B), et RsbU qui est responsable de la transduction des signaux 
de stress. Bien que les quatre gènes de l’opéron Sigma B de S. aureus montrent une forte 
homologie avec ceux présents chez B. subtilis, la taille totale de l’opéron Sigma B de S. aureus 
est inférieure de moitié à celle de B. subtilis.   
De nombreux facteurs de virulence ont été identifiés chez  S. aureus. On peut les répartir 
arbitrairement dans plusieurs grandes catégories en fonction de leur mécanisme d’action : (i) les 
exotoxines ou hydrolases endommageant les tissus ou les cellules sanguines (érythrocytes, 
leucocytes) ; (ii) les adhésines, qui sont des protéines de surface permettant l’attachement de S. 
aureus à des composantes cellulaires ou extracellulaires de l’hôte (ex. fibrinogène, fibronectin, 
collagène, élastine, etc.) et contribuant à la colonisation de l’hôte ; (iii) les composantes de 
surface (ex. capsule, protéine A) protégeant S. aureus du système immunologique de l’hôte ; (iv) 
les superantigènes (ex. toxine du choc septique, entérotoxine, etc.) produisant des réactions 
immunologiques excessives chez l’hôte ; (v) la formation de biofilm à la surface de certains 
tissus ou d’implants artificiels.  
Les deux protéines étudiées dans mon travail représentent un couple d’adhésines liant la 
fibronectine (en anglais : fibronectin-binding protein ; abbrév. FnBPs). Ces deux protéines, 
respectivement FnBPA et FnBPB, ont été étudiées en détail dans mon laboratoire d’accueil 
depuis >10 ans, car elles jouent un rôle central dans l’attachement de S. aureus à la matrice 
extracellulaire ainsi qu’à des matériaux implantés. Plus récemment, notre laboratoire a démontré 
que les FnBPs jouent un rôle essentiel pour l’endocytose de S. aureus par des cellules non-
phagocytaires (ex. cellules épithéliales et endothéliales, fibroblastes, ostéoblastes), un processus 
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qui permet aux staphylocoques intracellulaires d’échapper aux mécanismes de destruction 
phagocytaire ou antibiotique. 
D’autres expériences récentes effectuées dans notre laboratoire ont démontré que les 
souches de S. aureus résistantes aux fluoroquinolones augmentent leur adhérence à des surfaces 
recouvertes de fibronectine après croissance en présence d’une concentration sub-inhibitrice de 
ciprofloxacine. Le mécanisme moléculaire responsable de cet accroissement de l’adhérence de S. 
aureus est une augmentation de la synthèse de FnBPB, elle-même due à une transcription plus 
intense du gène fnbB. Des expériences de génétique moléculaire ont démontré que la synthèse 
accrue de FnBPB par l’exposition à la ciprofloxacine mettait à contribution le système RecA-
LexA de réparation de l’ADN bactérien.  
Mon travail expérimental décrit le rôle du facteur de transcription alternatif Sigma B dans 
l’augmentation de la production de FnBPs, aux niveaux transcriptionel et fonctionnel, chez des 
souches isogéniques de S. aureus résistantes aux fluoroquinolones. Une question additionnelle 
était d’évaluer en parallèle la stimulation de la transcription de FnBPs via le système RecA-
LexA, en incubant les souches isogéniques de S. aureus avec des concentrations sub-inhibitrices 
de ciprofloxacine. Le but de ce protocole était de tester si ces deux systèmes d’induction de 
synthèse des FnBPs pouvaient être stimulés indépendamment ou interféraient l’un avec l’autre. 
Des mutants isogéniques d’une souche quinolone-résistante de S. aureus exprimant trois niveaux 
différents d’activité de Sigma B ont été préparés par transduction phagique. La 1ère souche 
montrait une inactivation complète du gène synthétisant Sigma B, la 2ème souche exprimait une 
faible quantité basale de Sigma B qui ne pouvait pas augmenter en présence d’un stress, alors 
que la 3ème souche était complètement restaurée pour sa production de Sigma B et activable par 
un stress. D’un point de vue morphologique, la culture sur agar de ces différentes souches a 
confirmé les différences phénotypiques attendues : la souche dont le Sigma B est complètement 
restauré a montré une pigmentation orangée beaucoup plus intense que les deux autres souches, 
mais une production inférieure d’exotoxine alpha-hémolytique et de protéases secrétées dans le 
milieu ambiant. 
Les trois souches isogéniques de S. aureus exprimant différents niveaux d’activité de SigB 
ont montré une augmentation proportionnelle de la synthèse de FnBPs qui a entraîné une 
augmentation de leur attachement à la fibronectine. La présence accrue de FnBPs due à 
l’augmentation de Sigma B ou à l’exposition à la ciprofloxacine a été confirmée par cytométrie 
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de flux. L’accroissement de FnBPs liée à l’activité de Sigma B dans les souches isogéniques 
et/ou à leur exposition à la ciprofloxacine était le reflet d’une transcription accrue, testée par RT-
PCR en temps réel, de leurs gènes fnbB et dans une moindre mesure fnbA. D’autres mesures de 
transcription de gènes par RT-PCR en temps réel ont montré une diminution importante de la 
transcription du gène de l’exotoxine alpha-hémolytique et à l’inverse une très forte augmentation 
de l’activité transcriptionelle du gène codant pour la protéine A, chez la souche dont le Sigma B 
est complètement restauré par rapport aux deux autres souches. Une partie des changements 
transcriptionels observés chez les gènes codant pour les FnBPs, l’exotoxine alpha-hémolytique 
ou la protéine A s’explique par des changements d’activité de deux de leurs régulateurs globaux : 
(i) le régulateur global agr a montré une activité inversement  proportionnelle à l’activité du 
facteur Sigma B ; (ii) par contre, le régulateur global sarA a montré une activité directement  
proportionnelle à l’activité du facteur Sigma B, car il possède un promoteur spécifiquement 
activé par ce facteur de transcription.  
En conclusion, le facteur alternatif de transcription Sigma B chez S. aureus régule 
positivement les gènes fnbB et fnbA et augmente la quantité de protéines de surface agissant 
comme adhésines pour la fibronectine. La stimulation des FnBPs par l’activité du facteur Sigma 
B est due à l’activation d’un système de régulation indépendant du système LexA-RecA stimulé 
par la ciprofloxacine. Cependant la stimulation combinée des deux systèmes Sigma B et RecA-
LexA a un effet additif sur la production accrue de FnBPs et l’augmentation de l’adhérence de S. 
aureus à la fibronectine. La composition moléculaire de l’ensemble des facteurs des systèmes 
Sigma B et RecA-LexA reste en grande partie énigmatique et nécessitera d’autres études 
approfondies. 
Ces observations confirment expérimentalement la notion que le milieu hospitalier a un 
impact significatif sur la virulence des souches nosocomiales de S. aureus, en particulier celles 
du groupe MRSA, qui subissent une forte pression sélective par l’usage intensif de multiples 
agents antimicrobiens et l’émergence croissante de nombreuses résistances antibiotiques. 
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English summary 
 
The strong selective pressure of antibiotics and the increasing number of multi-drug 
resistant strains in hospitals have a significant impact on virulence properties of nosocomial 
strains of Staphylococcus aureus, in particular those exhibiting resistance to methicillin (MRSA). 
Recent experiments have shown that fluoroquinolone-resistant strains of S. aureus grown in the 
presence of subinhibitory concentrations of ciprofloxacin exhibit increased adhesion to 
fibronectin-coated surfaces. The molecular basis of this ciprofloxacin-promoted adhesion 
involves increased synthesis of two bacterial proteins (FnBPs) exhibiting specific binding to 
fibronectin via the contribution of the RecA-LexA DNA repair pathway. This work describes the 
contribution of the alternative transcription factor Sigma B (SigB), another bacterial stress 
response factor, to the upregulation of FnBPs as well as its interaction with the ciprofloxacin-
triggered RecA-LexA pathway. Isogenic mutants of a fluoroquinolone-resistant strain of S. 
aureus exhibiting different levels of SigB activity show a proportional increase of FnBP 
synthesis leading to enhanced bacterial adhesion to fibronectin-coated surfaces. Upregulation of 
FnBPs by SigB functional activity and ciprofloxacin exposure occur via independent pathways. 
Nevertheless, the combined stimulation of SigB-dependent and LexA-RecA pathways leads to 
additive effects on upregulation of FnBPs and increased bacterial adhesion to fibronectin. 
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A. GENERAL CHARACTERISTICS OF STAPHYLOCOCCI 
 
 
 
 
Staphylococci are spherical cells about 1 micrometer in diameter (figure 1). They grow 
in clusters because staphylococci divide in two planes. Staphylococci are found in association 
with skin, skin glands, and mucous membranes of warm-blooded animals, although some 
species can be isolated from processed animal sources such as meat and diary products, or 
from environmental sources, such as soil, dust, air, and water. 
Members of the genus are usually facultative anaerobes, capable of generating energy 
by respiratory or fermentative pathways. Most species have relatively complex nutritional 
requirements, usually requiring several amino acids and B vitamins. They are tolerant to high 
concentrations of NaCl and temperature ranging from 10°C to 45°C. Staphylococci belong to 
the low G + C (30 to 38 mol percent) group of the gram-positive bacterial phylogenetic group 
(Wilkinson, 1997). 
 
Taxonomy 
The genus Staphylococcus represents gram-positive, catalase-positive cocci that 
historically belonged to the bacterial family Micrococcaceae (Witte, 2000). Phylogenetic 
classification indicated that over 50% of predicted proteins encoded by the S. aureus genome 
are closely related to those in Bacilllus subtilis and Bacillus halodurans. They typically 
contain house-keeping genes, essential for bacteria to absorb nutrients from the environment, 
synthesize metabolic intermediates, and multiply. They possess bacteriophages, pathogenecity 
islands, transposons, and insertion sequence elements distributed over the genomes (Kuroda, 
2001). 
Figure 1. Scanning electron micrograph 
of S. aureus (Todar. K. 2003).
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Gram positive cell wall 
 
Figure 2. Gram positive cell wall. 
Gram positive cell wall is composed of a thick peptidoglycan (murein) layer and ribitol teichoic acids. 
Lipoteichoic acid, which may protrude on the surface through the peptidoglycan layer, is linked to the 
cytoplasm. Cell wall ribitol teichoic acid is covalently linked to the peptidoglycan layer. The cell walls of most 
gram-positive bacterial species have an extensive meshwork of peptidoglycan layer that is typically 15-30 nm 
thick. Peptigolycan polymers are cross-linked by pentaglycine bridges between L-lysine and the terminal D-
alanine, builiding a huge macromolecular murein sacculus around each bacterium  (Beveridge, 2000). 
  
Basic structure of S. aureus genome 
The staphylococcal genome consists of a single circular chromosome generally 
including prophages, transposons, insertion sequences, and other variable accessory elements 
plus irregularly present, autonomous plasmids. Staphylococcus aureus (S. aureus) genome is 
about 2.8 Megabase pairs long with approximately 2600 open reading frames. The genes for 
antibiotic resistance in S. aureus are located on plasmids, transposons, or on the chromosome 
(Kuroda, 2001).  
S. aureus NCTC 8325 has been the organism of choice for genetic and mapping studies 
of S. aureus chromosome. The parental strain is known to carry three proghages called φ11 , 
φ12, and φ13. However, UV-cured (prophage minus) derivatives, such as 8325-4 (RN 450) or 
RN6390 have been used for most genetic studies (Iandolo, 2002). 
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Figure 3. Circular representation of S. aureus chromosome (N315) (Kuroda, 2001). 
 
 
Whole genome sequences of two health-care-associated MRSA strains, N315 (figure 3) 
and Mu50, isolated in Japan in 1982 and 1997, respectively, and one community-acquired 
MRSA strain MW2 (MW standing for midwest USA) have been published (Kuroda, 2001; 
Baba, 2002). The three MRSA strains have closely related nucleotide sequences (99.7% 
identity between N315 and Mu50, 94.8% between MW2 and N315, and 94.7% between 
MW2 and Mu50). General features of the N315 and Mu50 genomes are described (Kuroda, 
2001). They have a low G+C content (average 33%), and possess five rDNA operons. The 
N315 and Mu50 genomes contain 2595 and 2697 open reading frames, respectively. Most of 
the nucleotide differences between strains N315 and Mu50 are due to insertion of mobile 
genetic elements. Both strains possess several bacteriophages, pathogenicity islands, 
transposons, and insertion sequence (IS) elements distributed over the genomes. Additionally, 
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each strain has a distinct plasmid carrying different antibiotic resistance genes (Kuroda, 
2001). 
 
Genomic islands (GI) 
A number of GIs, defined as chromosomal regions likely acquired from other strains or 
species, are found on the S. aureus chromosome. They are named according to the 
chromosomal loci where the islands are integrated. Some GIs confer pathogenicity while 
others confer antibiotic resistance. Among these islands, the staphylococcal cassette 
chromosome mec (SCCmec; mec standing for methicillin resistance) element carries antibiotic 
resistance genes (Ito, 2003). 
 
B. EPIDEMIOLOGY 
Many humans are regularly colonized by S. aureus, and asymptomatic colonization is 
far more common than infection (Chambers, 2001). Colonization of the nasopharynx, 
perineum, or skin, particularly if the cutaneous barrier has been disrupted or damaged, may 
occur shortly after birth and may recur anytime thereafter. Family members of a colonized 
infant may also become colonized. In some epidemics of MRSA, a relatively low level of 
nasal carriage (3%) has been found in hospital personnel, but more recent studies indicate a 
higher rate of MRSA nasal carriage in health care workers for endemic MRSA situations. The 
sharp increase in the prevalence of MRSA in many communities has led to consider 
outpatients as a potential source of contamination in an institution. Populations that are more 
susceptible to MRSA colonization include intravenous drug users, persons with dermatologic 
diseases, diabetes, and persons on kidney dialysis. Young children tend to have higher 
colonization rates, probably because of their frequent contact with respiratory secretions. 
Colonization may be transient or persistent and can last for years. 
 
Nosocomial infections 
S. aureus is a major pathogen of hospital-acquired infections. Colonization of healthy 
carriers represents a major source of nosocomial infections. A major concern of nosocomial S. 
aureus infections is the presence of endemic isolates exhibiting resistance to methicillin and 
frequently to several other antibiotics. The prevalence of methicillin-resistant S. aureus 
(MRSA) has increased in many countries over the world since 1980. The first strain of MRSA 
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was isolated in 1961 (Jevons, 1961), two years after the introduction of methicillin. MRSA 
mainly reside in environments in which there is a constant antibiotic pressure such as 
hospitals. Once endemically present, they are difficult to control and eradicate. A striking 
property of MRSA is their tendency to accumulate additional unrelated resistance 
determinants and incorporate them into their genome. Their adaptability and ready response 
to antibiotic selection has led to the evolution of MRSA strains resistant to almost all 
commonly used antibiotics. While vancomycin is still the antibiotic of choice (and frequently 
of last resort) for treating MRSA infections, reports of vancomycin-intermediate S. aureus 
(VISA) in Japan in 1997 (Hiramatsu, 1997) and later in other countries caused widespread 
concern among physicians. In 2002, the first vancomycin-resistant S. aureus (VRSA) isolates, 
exhibiting vancomycin MICs of 1024 and 32 µg/ml, respectively, were reported in Michigan 
and Pennsylvania (CDC, 2002a; CDC, 2002b). Currently, there is no antibiotic class that is 
uniformly effective against S. aureus (Robinson, 2004).  
 
MRSA prevalence in hospitals 
Since the mid to late 1990s, the prevalence of MRSA isolates in hospitals increased in 
Europe, the USA, and elsewhere. In one European study performed in 25 university hospitals, 
one-quarter of 3051 S. aureus isolates were MRSA, with a geographical bias towards higher 
rates in southern countries such as Italy (50.5%) and Portugal (54%), and lower rates in 
northern European countries, including the Netherlands (2%), Austria (9%) and Switzerland 
(2%) (Robinson, 2004; Enright, 2003).The National Nosocomial Infections Surveillance 
system (NNIS) reported a 40% increase in the rate of MRSA in 1999 compared to 1994-1998 
data (NNIS system report, 2000). MRSA infections are associated with increased morbidity, 
mortality and length of hospital stay, and represent a major financial burden on healthcare 
services (Nathwani, 2003; Cosgrove, 2003). Epidemiological studies confirmed that MRSA 
infections are more costly to manage (screening, treatment and isolation) than other types of 
infection (Rubin, 1999). They also highlighted the importance of hospital length of stay as a 
key determinant of the total cost of an episode of infection. In summary, MRSA are now 
endemic in many hospitals, and represent one of the leading causes of nosocomial pneumonia 
and surgical site infections and the second leading cause of nosocomial bloodstream 
infections. 
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Molecular structure of the methicillin resistance gene  
The structural gene for methicillin resistance, mecA, encodes a novel penicillin binding 
protein (PBP)-2’, which has reduced affinity for ß-lactam antibiotics (Hiramatsu, 1995; 
Chambers, 1988; Berger-Bächi, 2002). This gene is carried on a genetic element, 
staphylococcal chromosomal cassette (see below), which is a 20-67-kb DNA element which 
precisely inserts into the S. aureus chromosome at the orfX locus. SCCmec is found in other 
staphylococcal species from which it is presumed to have been transferred (Ito, 2003).  
The staphylococcal cassette chromosome mec (SCCmec) is a special family of 
staphylococcal genomic islands (GI) characterized by its cassette chromosome recombinases 
A (CcrA) and B (CcrB) (Hiramatsu, 2001; Ito, 2003; Enright, 2003) 
 
 
Figure 4. Structures of four types of  SCCmec. 
SCCmec is composed of two essential gene complexes, the ccr gene complex (orange) and the mec gene 
complex (gray). ccr gene complex is composed of ccrA, ccrB genes which are responsible for the mobility of 
SCCmec and some orfs surrounding them. mec gene complex is responsible for ß-lactam resistance. Other areas 
(light gray) of the SCCmec are non-essential, and are divided into three regions. Type-IV SCCmec is mostly 
composed of essential gene complexes  (Ito, 2001). 
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The ccr gene complex is composed of two site-specific recombinase genes, ccrA and 
ccrB, responsible for the mobility of SCCmec, and surrounding orfs of unknown function. 
The rest of the SCCmec is designated J regions (J stands for junkyard) that contain various 
genes or pseudo genes whose presence does not appear essential or useful for the bacterial 
cell.  
Figure 4 illustrates the structure of the four SCCmec types and their subtypes. Three 
types of SSCmec element (type I, II, III ) are found in hospital-acquired MRSA (HA-MRSA) 
strains and one type of SSCmec element (type IV) in community-acquired MRSA (CA-
MRSA). 
Type I SSCmec, a 34-kb element that was first described in 1960s MRSA isolates and 
does not contain any antibiotic resistance genes other than mecA.  
TypeII SSCmec, a 53-kb element, carries the type-2 ccr gene complex, which was 
identified in 1982 and is ubiquitous in Japan, Korea, and the United States. MRSA N315 and 
Mu50 carry type-II SCCmec, containing integrated copy of plasmid pUB110 and transposon 
Tn554 in the J region. 
Type-III SCCmec, the largest element at 67 kb, was identified in 1985 and is prevalent 
in Germany, Austria, India, and other South Asia and Pacific areas, containing integrated 
copy of plasmid pT181, transposon Tn554, and pseudo Tn554 that encode resistance to 
tetracycline, erythromycin, and cadmium, respectively.  
Type IV SCCmec includes four subtypes, whose sizes vary from 20 to 24 kb, and is 
much smaller than SCCmec types I-III. SCCmec type IVa is generally found in recently 
described (Okuma, 2002) community-acquired MRSA isolates (CA-MRSA). Types-IVa and -
IVb SCCmec do not harbor any antibiotic resistance genes except for mecA. The community-
acquired MRSA MW2 carry type-IVa SCCmec.  
 
Transmission of MRSA  
Recent molecular studies on the genetic origin of methicillin resistance in S. aureus 
have led to a greater understanding of the epidemiology of MRSA (Muto, 2003). De novo 
development of MRSA results when a strain of MSSA acquires a large genomic element 
SSCmec. Detailed genetic analysis of MRSA from diverse parts of the world suggests that the 
transfer of SSCmec from a MRSA strain to a MSSA strain occurred rarely, and therefore the 
worldwide emergence of MRSA mostly resulted from dissemination of only a limited number 
of types rather than frequent de novo introduction of new MRSA clones. These findings 
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suggest that most patients acquired their MRSA infection or colonization by transmission  
from other colonized patients or health care workers. 
Transmission of MRSA within and between healthcare facilities has been well 
documented using molecular typing techniques, such as pulsed-field gel electrophoresis 
(PFGE). Outbreaks involving clonal spread within single facilities have been frequently 
reported. Geographic clustering of closely related genotypes within cities and geographic 
regions has been described, suggesting that spread beyond the boundaries of a single hospital 
may occur. Transmission of MRSA from one city to another, from country to country, and 
even from continent to continent has been traced to the transfer of patients infected or 
colonized with MRSA.  
 
Mechanisms of transmission  
• Healthcare workers’(HCWs) hands is the major source of cross-transmission: in 
several studies, MRSA or VRE have been isolated from the hands, gloves, or 
both of the HCWs involved in the care of infected or colonized patients.  
• HCWs’ clothes: several investigators suggested that the contaminated HCWs’ 
clothing may result in the transmission of microbes from patient to patient;  
• Contaminated equipment, environment, and air (in the case of staphylococcol 
pneumonia). In one study, 42% of nurses’ gloves became contaminated with 
MRSA when they touched surfaces in the room of a patient with MRSA even 
without touching the patient. 
Prolonged hospital stay, use of broad spectrum antibiotics, greater number and 
longer duration of antibiotic use, stay in an ICU or burn unit, surgical wounds, poor 
functional status and proximity to another patient with MRSA constitute risk factors 
for MRSA acquisition (Muto, 2003). 
 
Control and preventive measures 
• Active surveillance cultures are essential to identify the reservoir for spread of MRSA 
and VRE infections and implement infection control guidelines. Many studies have 
shown that endemic and/or epidemic MRSA and VRE infections can be controlled by 
using surveillance cultures and contact precautions and has been proven to be effective 
(Pittet, 2000; Muto, 2003).  
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• Hand hygiene is an important measure for preventing MRSA transmission. Educating 
healthcare workers and patients on the importance of hand hygiene is very important 
for preventing MRSA transmission and has been proven to be effective (Pittet, 2000; 
Muto, 2003).  
• Contact precautions include wearing gloves, gowns and masks (if expected contact 
with patient or environment), regular cleaning of equipments and items. Jernigan 
(Jernigan, 1996) found a 16-fold reduction in transmission when contact precautions 
were implemented. 
• Antibiotic control may also decrease the risk of MRSA colonization. It has been 
shown that antibiotics in general and fluoroquinolone in particular must be used 
prudently in institutions where MRSA is endemic.  
• Eradication of colonization in HCWs is necessary, in particular in outbreak situations.  
• Information management: a hospital computer system can be used to store information 
regarding long-term isolation indicators for patients known to be colonized with 
MRSA or VRE. This was done at the University of Geneva Hospitals and resulted in a 
significant improvement in isolation of such patients on readmission (Pittet, 1996). 
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C. PATHOGENESIS OF S. AUREUS INFECTIONS 
S. aureus expresses many potential virulence factors including (figure 5): 
(1) surface proteins that promote colonization of host tissues or endocytosis;  
(2) surface components that may inhibit phagocytic engulfment (capsule, protein A);  
(3) membrane-damaging exotoxins that may lyse eukaryotic cell membranes (hemolysins, 
leukotoxin, leukocidin);  
(4) superantigens that may lead to indirect damage of host tissues and toxic shock symptoms, 
such as staphylococcal enterotoxins (SE), toxic shock syndrome toxin (TSST), exfoliative 
toxins (EFT). 
 
Figure 5. Potential virulence factors of S. aureus. 
  
S. aureus has been recognized as serious pathogens for over a century, causing a wide 
range of diseases ranging from benign or more severe skin infection to often fatal forms of 
endocarditis or septic shock. The diseases spectrum of S. aureus includes superficial skin 
lesions such as boils, styes and furuncles, abscesses, and serious infections such as 
bacteremia, central nervous system infections, endocarditis, osteomyelitis, pneumonia, 
urinary track infections, and syndromes caused by exotoxins, including bullous impetigo, 
food poisoning, scaled skin syndrome, and toxic shock syndrome (Fred, 2000). Despite large-
scale efforts to halt their spread, particularly in hospitals, S. aureus remain the major 
pathogens of community- and nosocomially-acquired bacteremia.  
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Surface protein adhesins 
S. aureus can adhere to host extracellular matrix (ECM) components to initiate 
colonization. Bacterial adhesion is mediated in main part by surface protein adhesins of the 
MSCRAMM (microbial surface components recognizing adhesive matrix molecules) family. 
In most cases, MSCRAMMs are covalently anchored to the cell wall peptidoglycan, in 
particular two fibronectin-binding proteins called FnBPA and FnBPB, a collagen-binding 
protein (Cna), and the fibrinogen-binding proteins clumping factor A (ClfA) and B (ClfB) 
(Vaudaux, 2000).  
 
 
 
 
Figure 6. Structural organization of the MSCRAMM (microbial surface components recognizing adhesive 
matrix molecules) proteins (a) Spa, (b) Cna, (c) ClfA and (d) FnBPA and FnBPB of S. aureus (Bisognano, 
2000a). ‘S’ represents the signal sequence; ‘R’ represents the Ser–Asp dipeptide repeats; ‘W’ represents the 
wall-spanning region; and ‘M’ represents the membrane-spanning region and positively charged residues. Wr is 
composed of an octapeptide repeat, and Wc is a non-repeated region. ‘A, B, C, D’ represent extracellular 
regions. The positions of the LPXTG motif is indicated. Asterisks indicate ligand-binding domains. 
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The molecular structure of these S. aureus surface proteins is shown on figure 6. Protein 
A (Spa), the archetypal LPXTG-anchored wall-associated protein, can bind to the Fc domain 
of immunoglobulin G (IgG) and inhibit opsonophagocytosis (Foster, 1998). The four other 
proteins, namely Cna, FnBPA, FnBPB, and ClfA are also anchored to the cell wall by the 
LPXTG (Leu-Pro-X-Thr-Gly) motif and clearly promote bacterial attachment to their specific 
ECM ligands. Another surface protein is the elastin-binding protein (Ebp, not shown on the 
figure) that is not a member of the LPXTG-anchored family. S. aureus can bind several 
additional host plasma proteins and ECM components, but the bacterial components which 
are responsible for binding have not been characterized to the same extent (Menzies, 2003). 
The role of these staphylococcal matrix-binding proteins are virulence factors was 
documented by in vitro and ex vivo adhesion studies of defective mutants and in experimental 
models of infections. ClfA-null mutants (defective in binding to fibrinogen) have reduced 
virulence in a rat model of endocarditis, suggesting that bacterial attachment to the sterile 
vegetations caused by damaging the endothelial surface of the heart valve is promoted by 
fibrinogen or fibrin (Moreillon, 1995). In addition, lactococci expressing recombinant FnBPA 
or ClfA have also increased virulence in the rat endocarditis model (Que, 2001). Similarly, 
mutants lacking the collagen-binding protein have reduced virulence in a mouse model for 
septic arthritis. Furthermore, the soluble ligand-binding domain of the fibrinogen, fibronectin 
and collagen-binding proteins expressed by recombinant methods can block to some extent  
interactions of bacterial cells with the corresponding host protein (Menzies, 2002). 
 
Fibronectin-binding proteins (FnBPs) 
S. aureus expresses either one or two FnBPs, FnBPA and FnBPB, which are encoded by 
two closely linked genes, fnbA and fnbB (Flock, 1987; Signäs, 1989; Jonsson, 1991; Greene, 
1995). At the N-terminus of the protein is the A region which contains a signal sequence that 
is responsible for translocation of each FnBP through the cytoplasmic membrane (figure 6). 
Both FnBPs share approximately 45% amino acid identity and can bind specifically to 
fibronectin in vitro. The C-terminus is composed of a hydrophobic membrane-spanning 
region (region M) and an LPXTG motif that is a target for sortase, a transpeptidase that 
covalently links FnBPs and other microbial surface proteins to the cell wall peptidoglycan. 
The fibronectin-binding D region located in the C-terminus is composed of three tandem 
repeats of 37 or 38 amino acids (D1, D2, and D3) in addition to one incomplete repeat (D4). 
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A fifth repeat, Du, is found approximately 100 amino acid residues N-terminal to D1. Each D-
repeat can bind specifically to fibronectin (Menzies, 2003; Schwarz-Linek, 2004). The D-
repeats are highly conserved between FnBPA and FnBPB (about 94% identity) and 
homologous repeats have been found in fibronectin-binding adhesins of various streptococcal 
species. The B repeat region is absent in FnBPB (Menzies, 2003).  
The ability to bind to the human protein fibronectin (Fn, figure 7) is a characteristic that 
has been reported for many pathogens (Joh, 1999). In S. aureus, binding to fibronectin-coated 
coverslips of the parental strain containing both fnbA and fnbB genes was equivalent to those 
of their isogenic single fnbA or fnbB mutants with a single fnb gene (Greene, 1995). In 
contrast, the double mutant of fnbA and fnbB was completely defective in adhesion.  
Through binding to fibronectin in the extracellular matrix and cell surface, the FnBPs 
mediate adhesion and endocytosis of S. aureus to a variety of cultured mammalian cells 
including those of endothelial origin, airway epithelium, explanted biomaterials and 
implanted intravascular catheters (Joh, 1999; Vaudaux, 1993; Vaudaux, 1995; Greene, 1995). 
In a large molecular epidemiological study, adhesion to immobilized fibronectin was greater 
for isolates associated with orthopedic implant-associated infection than for isolates 
associated with nasal carriage, endocarditis, septic arthritis, and osteomyelitis (Peacock, 
1999). Implanted biomaterials become coated with serum components including fibronectin 
and thus bacterial binding to fibronectin would be an important virulence determinant in this 
setting. This study demonstrated no difference in fibronectin binding between staphylococcal 
groups with one versus two fnb genes. 
The in vivo importance of FnBPs was further tested in animal models comparing the 
virulence of wild-type and mutant strains deficient in FnBPs (Greene, 1995; McElroy, 2002; 
Menzies, 2003). Since these experiments yielded rather variable results, we can suppose that 
the relative importance of the FnBPs in different infections may depend on the route of initial 
bacterial entry and dissemination, the affected tissue and the bacterial strain used (Menzies, 
2003; Schwarz-Linek, 2004). 
 
Role of FnBPs as invasins 
Excepting for the promotion of S. aureus attachment to host cells and to fibronectin-
coated biomaterials which are important mediators of infection in experimental endocarditis, 
FnBPs also mediate uptake of S. aureus (endocytosis) by cultured non-professional 
phagocytes using host fibronectin to bridge with integrins on the cell surface. Of particular 
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interest is the capacity of the FnBPs to act as invasins. S. aureus is classically considered as 
an extracellular pathogen, however, many investigators have demonstrated the ability of S. 
aureus to invade non-professional phagocytes such as various epithelial and endothelial cells 
in vitro (Sinha, 1999). The uptake of staphylococci by mammalian cells may provide a safe 
harbor for the bacteria from most antimicrobials and from the immune response. This 
intracellular invasion has been shown to be FnBP-dependent and to involve fibronectin. 
FnBP-deficient mutants have greatly reduced uptake into host cells, and antibodies directed 
against fibronectin reduce staphylococcal uptake (Menzies, 2002; Sinha, 1999; Sun, 1997). In 
fact, FnBP alone is sufficient for invasion of host cells without the need for other 
staphylococcal cofactors (Sinha, 2000). The host cell receptor involved in the uptake of S. 
aureus appears to be the fibronectin-binding integrin receptor α5β1. Fibronectin acts as a 
bridging molecule between the surface-bound FnBP and the host integrin α5β1 (Massey, 2001; 
Sinha, 1999; Sinha, 2000; Schwarz-Linek, 2004). 
 
Molecular structure of fibronectin  
 
Figure 7. Fibronectin molecular structure. 
Fibronectin is a large ubiquitous 
glycoprotein found in soluble form in 
plasma and in an insoluble multimeric form 
in the extracellular matrix (Potts, 1994; 
Proctor, 1982). It is also one of the many 
host proteins deposited on the surface of 
implanted biomaterials. In addition to 
fibronectin’s numerous functions including 
cellular adhesion, differentiation, and tissue 
repair after injury, fibronectin has adhesive 
sites for various molecules such as heparin, 
collagen, fibrin, and specific integrins.
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A fibronectin molecule consists of two nearly identical polypeptide chains joined by two 
disulfide bonds near their carboxyl ends (figure 7). Each polypeptide chain is folded into a 
series of globular domains linked by short, flexible segments. The globular domains have 
binding sites for ECM components or for specific receptors on the cell surface. The receptor-
binding domain contains the tripeptide sequence RGD (arginine-glycine-aspartate), which is 
recognized by fibronectin receptors (figure 7). In addition to the binding activities noted, 
fibronectin also has binding sites for heparin sulfate, hyaluronate, and gangliosides 
(glycosphingo lipids that contain sialic acid groups). The major binding site in fibronectin for 
the S. aureus FnBPs has been localized in the N-terminal type 1 module of this host protein. 
In addition, several groups have found another binding site for S. aureus towards the C-
terminus of fibronectin. 
 
 
 
D. MOLECULAR CONTROL OF S. AUREUS PATHOGENESIS 
 
S. aureus is a remarkably versatile organism. It is flexible and adaptable to its 
surroundings. This versatility depends on a tremendous range of adaptive or accessory gene 
systems. Most of the >100 genes coding virulence factors are either displayed on the bacterial 
surface or released into the surroundings. These enable the organism to evade host defences, 
to adhere to cells and the extracellular matrix, to spread within the host and to degrade cells 
and tissues, for both nutrition and protection. These virulence genes are sometimes designated 
as the virulon, even though they are not all exclusively devoted to pathogenesis (Novick, 
2003).  
 
Regulated expression of S. aureus virulence factors 
The production of virulence factors is tightly regulated to enabling bacteria to thrive in a 
hostile host environment (Cheung, 2004).  
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An extensive list of the tightly regulated virulence factors is provided in Table 1 
(Novick, 2003). 
Table 1. Staphylococcal excellular accessory proteins. Adapated from Novick, 2003. 
Gene Location Product Activity/function Timing 
Superantigens 
   sea Phage Enterotoxin A Food poisoning, TSS pxp 
   seb chrom Enterotoxin B Food poisoning, TSS pxp 
   sec chrom Enterotoxin C Food poisoning, TSS pxp 
   sed Plasmid Enterotoxin D Food poisoning, TSS pxp 
   eta ETA phage Exfoliatin A Scalded skin syndrome pxp 
   etb Plasmid Exfoliatin B Scalded skin syndrome pxp 
   tst SaPI1, 2, bov1 Toxic shock toxin-1 Toxic shock syndrome pxp 
Cytotoxins 
   hla Chrom α -Hemolysin Hemolysin, cytotoxin pxp 
   hlb Chrom β -Hemolysin Hemolysin, cytotoxin pxp 
   hld Chrom γ -Hemolysin Hemolysin, cytotoxin xp 
   hlg Chrom δ -Hemolysin Hemolysin, cytotoxin pxp 
   lukS/F PVL phage P-V leucocidin Leucolysin pxp 
Enzymes 
   SplA-F Chrom Serine protease-like Putative protease   
   ssp Chrom V8 protease Spreading factor pxp 
   aur   Metalloprotease   (aureolysin) Processing enzyme? pxp 
   sspB   Cysteine protease Processing enzyme?   
   scp   Staphopain   (protease II) Spreading, nutrition pxp 
   geh Chrom Glycerol ester   hydrolase Spreading, nutrition pxp 
   lip   Lipase (butyryl   esterase) Spreading, nutrition pxp 
   fme Chrom FAME Fatty acid esterification pxp 
   plc   PI-phospholipase C   pxp 
   nuc Chrom Nuclease Nutrition pxp 
   hys Chrom Hyaluronidase Spreading factor xp 
   coa Chrom Coagulase Clotting, clot digestion exp 
   sak Phage Staphylokinase Plasminogen activator pxp 
Surface proteins 
   spa Chrom Protein A Anti-immune, anti-PMN exp 
   cna Chrom Collagen BP Collagen binding pxp 
   fnbA Chrom Fibronectin binding protein A Fibronectin binding exp 
   fnbB Chrom Fibronectin binding protein B Fibronectin binding exp 
   clfA Chrom Clumping factor A Fibrinogen binding exp 
   clfB Chrom Clumping factor B Fibrinogen binding exp 
Capsular polysaccharides 
   cap5 Chrom Polysacch.   cap. type 5 Antiphagocytosis? pxp 
   cap8 Chrom Polysacch.   cap. type 8 Antiphagocytosis? pxp 
xp, throughout exponential phase; exp, early exponential phase only; pxp, post-exponential phase. 
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Expression and regulation of virulence in S. aureus 
The coordinated regulation of extracellular and cell wall virulence determinants during 
growth is due to contribution of global regulatory elements in S. aureus infections. They are 
controlled by a complex regulatory network that includes some two-component systems 
(TCS), an alternative sigma factor σB , and some transcription factors. Table 2 provides a list 
of the most important regulatory and transcription factors identified so far. 
 
Table 2. Virulence gene regulation and transcription units in S. aureus. Adapted from 
Novick, 2003. 
Regulatory unit Description Role 
Regulates many extracellular and cytoplasmic protein AgrACDB/RNAIII TCS, autoinduced by 
peptide and virulence genes 
SaePQRS TCS, autoinduced Regulates many extracellular protein genes 
ArlRS TCS Regulates autolysis and certain virulence genes 
SvrA Membrane protein Required for the expression of agr 
SrrAB TCS Regulates certain virulence genes at low PO2 
σB Active in late exponential phase; regulates many 
 
Alternative sigma 
factor 
virulence genes 
Contributes to agr induction under certain conditions; SarA Transcription factor 
pleiotropic repressor 
SarS Transcription factor Activates transcription of spa and possibly other surface proteins 
genes 
Represses transcription of hla and possibly other SarT Transcription factor 
exoprotein genes 
SarR Transcription factor Minor transcription factor for sarA and possibly sarS 
Rot Transcription factor Major transcription factor for hla and other exoprotein genes 
 
 
A simplified model presented in 1997 by Projan and Novick assumed that cell-wall 
proteins are actively synthesized during the exponential phase, coinciding with the tissue-
binding and colonization phases of infection. These cell-wall proteins include protein A, 
fibrinogen-binding, fibronectin-binding, and collagen-binding proteins (table 1). During 
transition from exponential to postexponential phase, the expression of cell-wall proteins is 
repressed, while the synthesis of extracellular toxins and enzymes predominates. The 
combined effects of proteolytic activities (e.g. V8 protease) and toxin on host cells (e.g. α-
toxin) and extracellular matrix components synthesized during the postexponential phase 
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likely facilitate the local invasion and hematogenous dissemination for infections. Figure 8 
shows the time course and population density-dependent regulation of virulence factors by 
global regulators (Novick, 2003). 
 
 
 
 
Figure 8. Regulation of virulence determinants in S. aureus by global regulatory loci 
(Cheung, 2004). 
 
In a more recent version of this model (Cheung, 2004), the synthesis of cell surface 
adhesins such as fibronectin-binding proteins during the exponential phase was found to 
coincide with the expression of SarA and Sae, suggesting potential regulation of both fnbps 
by these two loci. During transition from exponential to postexponential phase where the 
synthesis of cell wall proteins is repressed and extracellular toxins such as α-toxin are 
produced, a maximal expression of SarA and the ensuing activation of agr is assumed. Other 
complicated features of this model involve: (i) control of SarA expression by SarR, a SarA 
protein homolog, and SigB; (ii) control of agr by SarA, a quorum sensing AIP, a TCS called 
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ArlRS, MgrA/Rat/NorR and SvrA; (iii) activation of agr leading to up-regulation of another 
TCS system called Sae and down-regulation of a SarA homolog called Rot; (iv) eventual  
repression of two gene products called SarT and SarS; (v) repression of α-toxin by SarT and 
activation of protein A synthesis by SarS, thus explaining the effects of agr activation on 
these target genes.  
 
The agr system 
 
 
 
 
Figure 9. A schematic diagram of agr system, showing the two divergent agr promoters (P2 and P3) and their 
transcripts. Adapted from Arvidson, 2001. The P2 operon contains four genes, agrA, B, C and D. Two of these, 
agrC and agrA represent a two-component signal transduction pathway and the other two combine to generate a 
peptide AIP that is the activation ligand for the signal receptor. The function of the signaling pathway is to 
activate P2 and P3. The P3 transcript, RNAIII, regulates (directly or indirectly) transcription of many different 
genes. 
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The agr (accessory gene regulator) system is a two-component system (TCS), and 
involves in primary regulation of expression of the virulon in S. aureus. The agr locus was 
originally identified as a chromosomal Tn551 insertion resulting in decreased production of 
secreted toxins and increased production of coagulase and cell wall-associated protein A 
(Peng, 1988). Figure 9 shows the agr locus, consisting of an about 3-kb locus (Novick, 1993; 
Novick, 1999; Novick, 2000; Arvidson, 2001), containing two divergent transcription units, 
driven by promoters P2 and P3. The P2 operon consists of four genes, agrB, D, C, and A. 
agrA and agrC represent a classical two-component signal transduction system, of which 
agrC encodes the signal receptor and agrA the response regulator. The other two genes, agrB 
and D, combine to produce a small peptide, an autoinducing peptide, AIP. The AIP is a 7-9 
amino-acid internal cleavage product of AgrD. The AIP binds to the N-terminal 
transmembrane domain of the agr signal receptor, agrC, activating the agr TCS, of which 
AgrA is the response regulator. Activated AgrA then upregulates promoters P2 and P3. The 
512-nucleotide P3 transcript, RNAIII, is the intracellular effector of the target gene regulation 
(Novick, 1993), and RNAIII is also an mRNA encoding the secreted δ-toxin (hld), although 
δ-toxin is not involved in the regulation of virulence genes (Janzon, 1989; Janzon, 1990). 
The agr locus has been found in nearly all S. aureus strains tested. Although the agr 
locus is conserved throughout staphylococci, variations are seen in the agrB, C, and D 
sequences, resulting in the production of AIP molecules and sensors (AgrCs) with different 
specificities (Ji, 1997). Within S. aureus, four specificity groups have been identified (Ji, 
1997). Mutual cross-activation of the agr signaling pathway is observed within each group, 
while mutual cross-inhibition is seen between the groups. 
The agr locus, besides being activated by AIP and SarA, may also be activated by a 
positive feedback loop via the sarT and sarU pathway. In this pathway, activation of agr 
represses sarT. Repression of SarT leads to activation of sarU, an activator of agr. This will 
lead to amplification of the original agr signal.  
The agr system plays an essential role in up-regulating the expression of post-
exponentially expressed extracellular toxins and enzymes such as α- and β-hemolysins, 
enzymes (lipases, proteases, and nucleases) and toxins (toxic shock syndrome toxin and 
enterotoxins), and down-regulating the synthesis of cell-surface adhesions such as protein A, 
fibronectin-binding proteins and coagulase during transition from exponential to 
postexponential phase (Saravia-Otten, 1997; Dunman, 2001; Cheung, 2004). In addition, the 
role of the agr system during the infection process was supported in some studies by the 
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greatly attenuated virulence of agr mutants in some animal models of infection, including 
arthritis, subcutaneous abscesses, endocarditis, mastitis, and osteomyelitis (Collins, 2000). 
The mechanisms by which RNAIII controls the transcription of its target genes are unknown. 
RNAIII seems to regulate transcription in an indirect way by either sequestrating a regulatory 
protein, or by activating or inhibiting the translation of mRNA encoding for transcription 
factor (Novick, 1993; Arvidson, 2001). 
 
The sarA locus 
The sarA locus was identified in a Tn917 insertion mutant of the clinical S. aureus 
strain DB showing reduced fibrinogen binding (Cheung, 1992). The product of the sarA locus 
is a small (14.7 kDa) basic protein with predominantly alpha helical structure. SarA is 
transcribed from three distant promoters (P1, P2 and P3) and terminates at a common 3' end 
(Bayer, 1996). The P1 and P2 promoters are recognised by the vegetative sigma factor, σA, 
and are mainly expressed during early exponential phase of growth. SarA transcription from 
P2 promoter is inhibited by another homologue, SarR (Manna, 2001). P3 promoter is 
recognised by the alternative sigma factor, σB, and is induced as the cells enter the 
postexponential phase of growth (Bayer, 1996; Manna, 1998).  
 
 
Figure 10. Physical map of sar locus. Promoter positions are labelled P1, P2, and P3. The arrows depict the sar 
transcripts. The distances between the 5' ends of the transcripts and the start codon of sarA are expressed by 
negative position numbers. P3 is σB-dependent, P1 and P2 are σA-dependent.  
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SarA binds as a dimer to AT-rich sequences distributed widely in the AT-rich 
staphylococcal genome, including the 5' regions of several genes. Some investigators 
described multiple SarA binding sites in the intergenic region between agr promoters P2 and 
P3, suggesting the possibility of co-operativity (Rechtin, 1999), whereas others have 
identified only one site (Morfeldt, 1996; Chien, 1998b). It seems there is no consensus on the 
SarA binding site.  
In addition to its effect on agr, sarA appears to regulate transcription of a number of 
virulence genes in an agr-independent way. Collagen binding protein (cna) is supressed by 
sarA (Lindsay, 1999), transcription of protein A (spa) was supressed by sarA (Cheung, 1997), 
while transcription of α-toxin gene (hla) and fnbA was activated by sarA (Chan, 1998a; 
Chien, 1999; Wolz, 2000). 
The importance of sarA in virulence has been demonstrated in some animal models of 
infection (Cheung, 1994; Booth, 1997). Using the GFP reporter gene, the sarA promoters 
were differently expressed in vitro and in a rabbit endocarditis model (Cheung, 1994). The sar 
P2 promoter, which was almost silent in vitro, became highly activated in vivo (Cheung, 
1994). However, there is no definitive consensus on upregulating effects of SarA. The 
reduced fibronectin-binding activity observed with sarA mutants may not be at the level of 
transcription and may be a consequence of increased proteolytic activity relased 
extracellularly by these sarA mutants (Blevins, 2002).  
A number of proteins that are homologous to SarA have been found in the S. aureus 
genome (www.ncbi.nlm.nih.gov) and confirmed by N315 and MW2 sequencing projects 
(Kuroda, 2001). This group of proteins, called ‘the SarA protein family’ (Cheung, 2004), 
includes five previously characterized SarA homologs (SarA, -R, -S, -T and -U), as well as 
four other as yet uncharacterized homologues SarV, SarX, SarY, SarZ. Rot, a repressor of α-
toxin synthesis, also shares homology with the smaller SarA homologues (McNamara, 2000). 
A recent microarray analysis has revealed that Rot has broad regulatory effects on genes 
belonging to the agr regulon and generally acts counter to agr, downregulating genes 
encoding secreted proteins and upregulating surface protein genes (Said-Salim, 2003). 
 
σB – alternative sigma factor B (Sigma B)  
A typical bacterial RNA polymerase has six subunits whose molecular weight exceeds 
4,000,000, making it one of the largest bacterial enzymes. RNA polymerase holoenzyme has 
two identical α subunits, two very large subunits called β and β', one ω subunit, and the σ 
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factor. α2ββ'ω forms the catalytically competent RNA polymerase core enzyme (E) which is a 
permanent part of the RNA polymerase. RNA polymerase core enzyme (E) is capable of 
elongation and termination of transcription, but is unable to initiate transcription at specific 
promoter sequences. Binding of the σ subunit to E forms the holoenzyme (E-σ) that directs 
the multisubunit complex to specific promoter elements and allows efficient initiation of 
transcription (Borukhov, 2002; Burgess, 2001). Therefore, σ factors provide an elegant 
mechanism in eubacteria to allow simultaneous transcription of a variety of genetically 
unlinked genes, but sharing the same promoter specificities. Because σ factors are powerful 
regulatory effectors, the molecular mechanisms of controlling their synthesis or activity are of 
fundamental importance. 
In addition to the housekeeping sigma subunits, σ70 or σA, most bacteria produce one or 
more additional σ subunits, termed alternative σ factors, which direct the respective E-σ 
complex to distinct classes of promoters that contain alternative σ factor-specific sequences. 
At least six alternative σ factors are produced by the enteric bacterium Escherichia coli. 
Genomic sequence analysis suggests that several alternative σ factors also exist in different  
pathogenic species such as Treponema palladium (4 alternative σ factors), Vibrio cholerae (7 
alternative σ factors), Mycobacterium tuberculosis (12 alternative σ factors), and 
Pseudomonas aeruginosa (23 alternative σ factors) (Bischoff, 2004). 
σB has been identified and shown to be involved in virulence, pathogenicity, and the 
ability to survive under extreme conditions when bacterial cells are exposed to stress 
conditions such as heat, ethanol, acid, salt, oxidative agents, and/or carbon depletion (van 
Schaik, 2004; Ferreira, 2001; Benson, 1993; Volker, 1999) in gram positive bacteria including 
Bacillus, Listeria, and Staphylococcus (Brody, 1998; Ferreira, 2001; Hecker, 1998; Kies, 
2001; Wu, 1996; Kullik, 1997). Two alternative σ factors, σB and σH, have been identified in 
S. aureus (Kullik, 1997; Wu, 1996). σH has only recently been characterized as a bona fide S. 
aureus sigma factor, which is involved in the transcriptional regulation of DNA competence 
factors (Morikawa, 2003). 
The genetic organization of the S. aureus sigB operon (Kullik, 1997; Wu, 1996) closely 
resembles that of the well-characterized operon of the soil-borne gram-positive bacterium 
Bacillus subtilis. In B. subtilis, the expression of several heat-shock or general stress genes is 
under the control of the alternative sigma factor, σB (Boylan, 1992; Boylan, 1993a; Boylan, 
1993b). σB activity is regulated post-translationally by a complex network of protein-protein 
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interactions governed by a variety of environmental or metabolic stresses such as heat shock, 
osmotic shock, ethanol treatment, or entry into stationary growth phase (Boylan, 1992; 
Boylan, 1993a; Boylan, 1993b). The proteins involved in this regulation are encoded by the 
rsb genes (regulators of Sigma B), which together with the sigB structural gene are located in 
the eight-gene σB operon (Boylan, 1992; Boylan, 1993a; Boylan, 1993b). The current model 
for σB activation in B. subtilis involves the regulatory proteins RsbU, RsbV and RsbW, as 
well as RsbR, RsbS, RsbT, and RsbX (Wise, 1995; Hecker, 1998). 
 
 
Figure 11. Similarity in organization of the operons of S. aureus and B. subtilis. Adapted from Wu, 1996. ORFs 
are indicated by arrows. Similarity between the predicted products of the corresponding genes are shown with 
percentages. 
 
The S. aureus sigB operon, like B. subtilis, comprises the genes rsbU, rsbV, rsbW and 
sigB (Wu, 1996; Kullik, 1997) which shows close similarities to the B. subtilis sigB operon, 
both in overall organization and in primary sequences of the gene products (figure 11). 
However, the sigB operon in S. aureus represents only 50% of the sigB operon size in B. 
subtilis, thus suggesting that this stress response pathway plays a less important physiological 
role in S. aureus compared to B. subtilis.  
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Figure 12. Proposed model for regulation of σB in S. aureus. Adapted from Bischoff, 2001a.  
RsbW is an anti-σB protein, it can form mutually exclusive complexes with σB or its antagonist, RsbV. RsbV is 
normally inactive due to phosphorylation by RsbW and thus is unable to complex with RsbW, leaving RsbW 
free to interact with σB. When σB binds to RsbW, it is unable to aggregate with the RNA polymerase core 
enzyme (E) to form an active holoenzyme (E-σB). Upon stress, an σB activator RsbU is active and 
phosphorylates RsbV-P. Un-phosphorylated RsbV complexes highly and specifically with RsbW, leaving σB 
free to form the holoenzyme (E-σB). 
 
As in B. subtilis, the σB operon of S. aureus is regulated post-translationally by rsbU, 
rsbV, and rsbW. The anti-sigma factor, RsbW, binding to σB  and inactivates σB during 
exponential phase (Miyazaki, 1999). In response to stress or starvation, RsbW is captured by 
the active form of the antagonist protein RsbV, leading to the release of σB, leaving the σB 
free to form an active σB holoenzyme. The activity of RsbV is controlled by its 
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phosphorylation state. Stress and starvation enhance the level of non-phosphorylated RsbV, 
which is the form that can bind to RsbW (figure 12). 
Discovering the role of σB in S. aureus has been delayed because of the presence of an 
rsbU mutation in 8325-4 (RN6390) which has been used most frequently for molecular and 
physiological analyses in laboratories. 8325-4 (RN6390) has a 11-bp deletion in rsbU which 
encodes for a positive regulator of σB function, and produces a strong defect in σB activity 
(Giachino, 2001). Derivatives of 8325 strains show important differences from the strains 
which have a complete rsbU. The differences of derivatives of 8325 strains include a 
reduction in the lag phase of growth, a decrease in pigmentation, and decreasing starvation 
survival (Kullik, 1998), etc. However, rsbU defective strains are not totally deficient in σB 
function (Palma, 2001), as pigment synthesis can be induced by subinhibitory clindamycin, 
and it is suggested that this may involve σB activation via RsbP (Novick, 2003). A small 
fraction of S. aureus clinical isolates are non-pigmented and overproduce various exoproteins 
(Novick, 2003).  
In S. aureus, σB feeds into the global regulatory network governing the expression of 
virulence genes, acting mostly through other regulatory genes and transcription factors, but 
also acting directly on those few that have σB-dependent promoters. σB recognizes a specific  
motif [GTTT(N14-17)GGGTAT] that has been identified for 23 different S. aureus genes 
(Gertz, 2000), including one of the three sarA and one of the three sarS promoters, plus genes 
encoding transport functions and others involved in generating NADH2. σB also regulates the 
activity of other genes that do not contain a σB promoter but are indirectly regulated by σB-
dependent transcription factors. 
The S. aureus σB factor has been shown to be involved in following functions: 
(1) σB involves in protecting the cell from various environmental stresses (Kullik, 1997; 
Gertz, 2000), activated by environmental stress and energy depletion (reduced ATP/ADP 
ratio), as well as environmental stimuli such as ethanol (Chan, 1998b) and salicylic acid 
(Kupferwasser, 2003). 
(2) σB involves in influencing the expression of several global virulence regulators, 
including sar (Bischoff, 2001b; Deora, 1997; Gertz, 2000; Manna, 1998; Cheung, 1999), sarS 
(also known as sarH1) (Bayer, 1996; Tegmark, 2000; Nair, 2003; Bischoff, 2004), and 
RNAIII (Bischoff, 2001b; Horsburgh, 2002). Some studies reported that σB can increase sarA 
expression while simultaneously reducing the RNAIII level in a growth phase-dependent 
manner (Bischoff, 2001b). 
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(3) Alkaline shock protein (asp23) is exclusively controlled by a functional SigB 
(Giachino, 2001; Gertz, 1999). σB upregulates some exoprotein genes at some growth stages, 
in particular coa and the P3 promoter of sarA which have σB-dependent promoters (Miyazaki, 
1999; Nicholas, 1999; Deora, 1997; Nair, 2003); clfA is transcriptionally regulated by σB 
(Nicholas, 1999; Nair, 2003); σB downregulates spa, hla (Ziebandt, 2001; Giachino, 2001; 
Horsburgh, 2002; Cheung, 1999; Nicholas, 1999); σB also influences the expression of some 
other genes including lipases (Kullik, 1998; Ziebandt, 2001), proteases (Horsburgh, 2002; 
Karlsson, 2001; Karlsson, 2002; Ziebandt, 2001), and thermonucleases (Kullik, 1998; 
Ziebandt, 2001). 
(4) The production of biofilms by S. aureus may be controlled  by σB (Rachid, 2000). 
(5) The ability of S. aureus to bind to various host-cell matrix proteins such as 
fibrinogen and fibronectin is influenced by σB (Kullik, 1998; Cheung, 1999; Ziebandt, 2001; 
Kies, 2001; Nair, 2003; Renzoni, 2004). 
(6) Besides regulating virulence determinants, σB has been suggested to contribute to 
expression of resistance to methicillin, vancomycin, and teicoplanin (Bischoff, 2001a; Singh, 
2003; Renzoni, 2004). 
 
 
 39
 
E. MECHANISMS OF ACTION OF ANTIMICROBIALS 
 
Currently available antimicrobial agents are targeting key components of cell wall 
synthesis, protein synthesis, RNA synthesis, DNA synthesis, or intermediary metabolism (table 
3). 
Bacterial cell wall synthesis has been the target which are most extensively exploited for 
antimicrobial development. The components of the cell wall synthesis machinery are appealing 
antimicrobial targets because of the absence of counterparts in human, thereby providing intrinsic 
target selectivity. β-Lactams as transpeptidase inhibitors thus block the conversion of immature 
to mature peptidoglycan (Hooper, 2001a). Vancomycin is a glycopeptide that is known to bind 
tightly to the terminal D-ALA-D-ALA of the peptide side chain of the immature peptidoglycan. 
Thus, vancomycin produces a block at the same step as β-lactams by producing steric hindrance 
to transpeptidase action, thereby preventing conversion of immature to mature peptidoglycan.  
 
Table 3. Bacterial targets of antimicrobial agents (Hooper, 2001a) 
    
Bacterial targets Antimicrobial agent 
Cell wall synthesis β-Lactam 
 Glycopeptides 
Protein synthesis Aminoglycosides 
 Macrolides 
 Lincosamides 
 Ketolides 
 Streptogramins 
 Tetracyclines 
 Chloramphenicol 
 Oxazolidinones 
RNA synthesis Rifamycins 
DNA synthesis Coumarins 
 Naphthyridines 
 Quinolones 
 2-Pyridones 
Intermediary metabolism Sulfonamides 
  Trimethoprim 
 
 
Mechanisms of fluoroquinolone action 
The fluoroquinolones are antibacterial agents widely used in clinical medicine. In 
addition to nalidixic acid, the original non-fluorinated member of the quinolone drug class, 
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several derivatives have been developed, such as norfloxacin, menoxacin, lomefloxacin, 
pefloxacin, ciprofloxacin, fleroxacin, ofloxacin, levofloxacin, sparfloxacin, grepafloxacin, 
tosufloxacin, temafloxacin, and trovafloxacin. Some of these agents have been removed from 
the market because of toxicity. Initial members of this class were used largely for treatment of 
infections caused by facultative gram-negative bacteria, gram-positive bacteria and also 
against anaerobic bacteria. The multiple clinical indications for ciprofloxacin and ofloxacin, 
in particular, have led to extensive use of these compounds for over a decade (Hooper, 1999; 
Hooper, 2000).  
 
 
Figure 13. Formation of fluoroquinolone complexes with topoisomerase IV and DNA gyrase on E. coli DNA 
as barriers to progression of the multicomponent DNA replication complex (Hooper, 2002). 
ParC and ParE are E. coli homologs of GrlA and GrlB S. aureus topoisomerase IV, and GyrA and GyrB are 
subunits of DNA gyrase. DnaB, primase, PriA, and polymerase are components of the DNA replication 
complex. Q represents quinolone molecules. 
 41
Dual targets  
Fluoroquinolones have two major enzyme targets in bacterial cells, namely DNA 
gyrase and topoisomerase IV. Both targets are essential for bacterial DNA replication 
(Hooper, 2001a; Hooper, 2001b; Hooper, 2002). 
DNA gyrase is composed of two GyrA subunits and two GyrB subunits in both E. coli 
and S. aureus. DNA gyrase is the only bacterial enzyme that introduces negative super-
helical twists into DNA. Negatively super-twisted DNA is important for initiation of DNA 
replication. DNA gyrase also facilitates DNA replication by removing positive super-helical 
twists that accumulate ahead of the replication fork as a result of the transcription of certain 
genes. Topoisomerase IV are composed of two subunits of ParC and two subunits of ParD in 
E. coli, which are homologous to GrlA, and GrlB in S. aureus. Topoisomerase IV acts in the 
terminal stage of DNA replication, allowing for the decatenation (superaction) of inter-linked 
daughter chromosomes so that segregation into daughter cells can occur. 
As shown by figure 13, fluoroquinolones interact with complexes of gyrase or 
topoisomerase IV with DNA, leading to trapping of the complex and blocking the 
progression of the DNA polymerase contributing to DNA replication. Subsequent events, as 
yet poorly defined, which probably involve generation of an irreparable DNA break triggered 
by this block, ultimately result in bacterial-cell death (Hooper, 2002).  
 
Mechanisms of fluoroquinolone resistance  
1. Alterations in drug targets 
The most important mechanism of fluoroquinolone resistance is mediated through 
altered target enzymes. Importantly, resistance arises stepwise. The resistance mutations 
cluster in the "quinolone resistance-determining region" (QRDR) of GyrA. A common model 
shows that amino acids in the QRDR of GyrA alter the structure of the site of quinolone 
binding near the interface of the enzyme and DNA, and the resistance is then caused by 
reduced drug affinity for the modified enzyme-DNA complex (Schmitz, 2002). 
The results of studies done with S. aureus indicated that, in contrast to E. coli, 
topoisomerase IV was the primary quinolone target in this species. Mutations in GrlA 
represent the first step towards acquisition of high-level resistance, but is not generally 
sufficient to cause clinical resistance to ciprofloxacin or other more potent fluoroquinolones.  
High-level resistance requires a second mutation in GyrA besides GrlA thus increasing 
quinolone MICs by >16-fold compared to MICs for susceptible isolates of S. aureus.  
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Interestingly, most MRSA clinical isolates express high levels of fluoroquinolone 
resistance mediated by combined mutations in GrlA and GyrA. Table 4 shows the most 
common mutations in GyrA and GrlA of S. aureus.  
 
Table 4. Common mutations in GyrA and GrlA and the corresponding MICs of ciprofloxacin for clinical 
isolates of S. aureus. Adapted from Schmitz, 2002. 
      
                Amino acid change Ciprofloxacin MIC (µg/ml) 
GyrA ParC/GrlA   
- - 0.25 
- Ser80Phe/Tyr 2-16 
Ser84Leu nt 16 
Glu88Lys Ser80Phe 16-32 
Ser84Leu Ser80Tyr 16 
Ser84Leu Ser80Phe/Tyr 12.5 - 800 
Ser84Leu Glu84Lys 100 - 800 
Ser84Leu Ser80Phe/Tyr + Glu84Lys 100 - >800 
Glu88Lys Ser80Phe + Glu84Val 32 - 256 
-, no mutation; nt, not tested.  
 
2. Increased efflux of fluoroquinolones 
All bacteria have proteins inserted into the cytoplasmic membrane that have important 
physiological functions as transporters of various substances into and out of the cell. Efflux 
pumps that can remove substances from the cytoplasm and from the cytoplasmic membrane 
have been found in all bacteria studied, and the general role of many such pumps is thought 
to remove toxic substances from the cell and its membrane (Hooper, 2002). Among these 
efflux pumps are those that can remove antibiotics from the cell, called multidrug resistance 
(MDR) pumps which can remove multiple antibiotics. MDR efflux pumps are normally 
present in most bacteria. Inactivation of some pumps can lead to hypersusceptibility to 
fluoroquinolones. 
In S. aureus, low-level resistance to ciprofloxacin can result from increased expression 
of a pump called NorA (Fournier, 2000). The effect of increased NorA expression on 
gatifloxacin and ciprofloxacin activity was investigated. When overexpression of the NorA 
efflux pump was effected through a single mutation of the promoter region of the norA gene, 
the MIC of ciprofloxacin increased 2- to 4-fold (from 0.25 to 0.5 1.0 µg/ml). The same 
mutation was shown to cause an 8-fold increase in the MIC of norfloxacin. Overexpressing 
NorA, the MICs of sparfloxacin and gatifloxacin were less affected than those of 
ciprofloxacin and norfloxacin (Ng, 1994; Ng, 1996; Hooper, 2000; Fournier, 2000). 
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SOS response 
The discovery of SOS response system came from studies on the effect of UV 
irradiation on E. coli. In E. coli, these potentially fatal lesions induce transcription of about 
20 DNA repair genes. This is known as the SOS response (Walker, 1985). The central 
regulatory element of the SOS pathway is the LexA repressor, which binds to the operators 
of SOS genes with a high affinity, thereby inhibiting transcription. Other requirements for 
induction of the SOS response depend on the type of DNA damage, but genetic analyses 
have shown that both the RecA and RecBCD enzymes — the two initiators of dsDNA break 
repair and homologous recombination — are essential for SOS induction in response to 
dsDNA breaks (Anderson, 1998; Janion, 2001). 
In contrast to E. coli, the major components of the SOS response pathway in S. aureus 
are mostly unknown. 
 
Induction of SOS response by quinolones  
The quinolones are potential inducers of the SOS regulon (Drlica, 1997), involving 
three major proteins in E. coli, RecA, RecBCD, and LexA. The early event is the generation 
of an inducing signal, which consist of short oligonucleotides and/or single-stranded DNA 
breaks. The damaged segments of nucleic acids activate RecA, which subsequently interacts 
with LexA protein and lead to auto-cleavage of LexA protein. LexA cleavage removes the 
repression of genes of the SOS regulon. 
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Figure 14. Model for SOS response in E. coli (Anderson, 1998). 
(A) DNA damage produces a dsDNA break.  
(B) RecBCD enzyme processes the broken DNA, degrading 3′→5′ until a χ site is recognized, at which 
time RecBCD enzyme pauses; the 3′→5′ exonuclease activity is attenuated; and RecA protein is 
loaded onto the χ-containing DNA strand within an ssDNA loop.  
(C) The nuclease polarity is then switched, with continued degradation occurring 5′→3′, leading to the 
production of a 3′ ssDNA overhang that is coated with RecA protein. 
(D) This activated RecA nucleoprotein filament that is assembled on the χ-containing ssDNA stimulates 
the self-cleavage of LexA repressor.  
(E) SOS genes are repressed by the binding of the LexA repressor to the operator (OP). The cleaved LexA 
protein no longer binds the promoter, thereby derepressing transcription. 
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Section II. EXPERIMENTAL STUDY 
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A. ORIGINS AND AIMS OF THIS STUDY 
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Previous studies performed in the research laboratory of the Division of Infectious 
Diseases revealed that fluoroquinolone-resistant (Q-R) grlA gyrA strains of S. aureus grown 
in the presence of sub-MIC levels of ciprofloxacin (CFX) expressed increased levels of 
FnBPs and showed significantly higher attachment to in vitro fibronectin-coated or explanted 
polymer surfaces (Bisognano, 1997; Bisognano, 2000). This increase was selectively 
expressed in Q-R grlA gyrA double mutants, as opposed to grlA or gyrA single mutants or 
susceptible parental strains. The CFX-triggered response by S. aureus NCTC 8325 strain 
RA1, carrying combined grlA gyrA mutations, involved increased transcription of fnbB gene 
in contrast to fnbA gene. The response was due to increased promoter activity of the fnbB 
gene. Inhibition of this CFX-promoted response by rifampin pretreatment confirmed that it 
occurred at a transcriptional level (Bisognano, 2000).  
A recent study (Bisognano, 2004) further analyzed the molecular mechanisms of CFX-
promoted adhesion. Inactivation of recA, the central activator of SOS and DNA repair 
pathway, abolished the CFX-triggered upregulation of fnbB gene. The study also revealed that 
recombinant LexA, another key component of the SOS response, exhibited specific binding to 
the fnbB promoter region. These data provided evidence for a role of the still incompletely 
characterized RecA-LexA-dependent pathway in the CFX-triggered FnBPs upregulation in Q-
R S. aureus (Bisognano, 2004).  
Sigma B (σB) is a transcription factor contributing to virulence and bacterial survival 
under stress conditions (see σB in section II). The studies from other laboratories (Bischoff, 
2001; Nair, 2003) showed that SigB could also upregulate expression of FnBPs. The aims of 
this experimental study were to (i) evaluate whether SigB contributed in an additive manner 
to the ciprofloxacin-triggered upregulation of FnBPs by using the isogenic derivatives of Q-R 
grlA gyrA strain RA1, exhibiting widely different functional levels of SigB activity; (ii) 
evaluate the potential contribution of global regulons agr and sarA to either the SigB- or 
ciprofloxacin- modulated effects on fnbA or fnbB transcription.  
These results provide evidence that optimal expression of a stress response factor and 
triggering of a drug-induced DNA repair system may independently, but in an additive 
manner, significantly promote FnBPs-mediated S. aureus adhesion. 
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B. MATERIALS AND METHODS 
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1. Bacterial strains 
Strain RA1 is a quinolone-resistant (MIC of ciprofloxacin: 32 µg/ml) mutant of S. 
aureus NCTC (National Culture Type Collection) 8325 strain (Bisognano, 2004). Like all 
members of the NCTC 8325 family, strain RA1 has a natural 11 bp deletion in rsbU gene thus 
yielding a defective truncated RsbU protein. Strain RA1 has one point mutation in grlA (Ser 
80 Phe) and another point mutation in gyrA (Ser 84 Leu). The first mutation in topoisomerase 
IV (grlA) brings a low level of quinolone resistance (MIC of ciprofloxacin: 2 µg/ml). When 
the first mutation combines with the second mutation in gyrase (gyrA), it generates a high 
level of quinolone resistance (MIC of ciprofloxacin: 32 µg/ml) (Bisognano, 2004). 
Strain TE1 is a Tn551 insertion sigB mutant of RA1 (Estoppey, 2003). TE1 was 
constructed by transducing RA1 with a phage lysate of strain ALC1001 (kindly provided by 
Cheung, A.L.) (Cheung, 1999; Wu, 1996) carrying the sigB mutation.  
The correct insertion of transposon Tn551 in the sigB gene of TE1 was confirmed by 
PCR, using the primers P1 (located in the end of rsbW gene) and P2 (located in the beginning 
of Tn551), which yielded a 832-bp product as expected (TE1, figure 1). No equivalent PCR 
product was found in strain RA1 (figure 1).  
 
Strain TE2 (Estoppey, 2003) is a derivative of RA1 whose SigB functional activity was 
restored by transducing RA1 with a phage lysate prepared from strain rsbU+ V+ W+ sigB+ Tcr 
GP268 (kindly provided by M. Bischoff) (Giachino, 2001).  
The PCR used to amplify the region of rsbU gene that encompassed the 11-bp deletion 
in rsbU sigB+ parent RA1, which was restored in the rsbU+ sigB+ strain TE2, yielded a 88 bp-
800 bp
TE1 RA1Std
832 bp
200 bp
400 bp
Figure 1. (left) 832-bp product of PCR from P1 and P2 was present TE1, and absent in RA1. (right) 
The positions of the primers used to perform PCR.
Tn 551
P1 P2
P3
rsbWrsbVrsbU
sigB gene
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product in TE2 compared to a 77 bp-product in RA1. These data confirmed that TE2 had a 
restored rsbU gene (figure 2). 
 
 
 
2. Determination of ciprofloxacin susceptibility 
The minimum inhibitory concentrations (MICs) of ciprofloxacin (CPX) for 
fluoroquinolone-resistant strains RA1, TE1, and TE2 were determined by a macrodilution 
method using cation-adjusted Mueller-Hinton Broth (MHB; Difco) and a standard inoculum 
of 106 CFU/ml, according to the National Committee for Clinical Laboratory Standards 
(NCCLS) (NCCLS, 2000). 
 
3. Detection of pigmentation  
The pigmentation of the sigB null strain TE1, the rsbU sigB+ parent RA1, and the rsbU+ 
sigB+ strain TE2 was observed after streaking on Mueller-Hinton agar (MHA) for 48 h at 
37°C. 
 
4. Detection of hemolysin  
2 µl late-logarithmic-phase (5 h) cultures in MHB of the sigB null strain TE1, the rsbU 
sigB+ parent RA1, and the rsbU+ sigB+ strain TE2 were spotted on sheep blood agar (SBA) 
for 24 h at 37°C to detect α-toxin, and then 24 h at 4°C to detect β-toxin. The clear hemolytic 
zones around the bacterial growth after the first 24 h of incubation at 37°C were produced by 
TE2   RA1
rsbU+
TE2
rsbV
rsbU¯ rsbV
RA1
11-bp deletion
Std
88 bp
77 bp
p1
p2
p2
Figure 2. (left) PCR products in rsbU+ sigB+ strain TE2 (88 bp) and its rsbU sigB+ parent RA1 (77 bp). (right) The positions 
of primers used to perform PCR.
p1
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α-toxin. The halo effects around the clear zones after the second 24 h of incubation at 4°C 
detected hot-cold hemolysis produced by β-toxin. Strain ATCC (American Type Culture 
Collection) 25923 was used as a positive control strain for β-toxin. 
 
5. Detection of protease activity on casein agar plates 
2 µl of exponential phase cultures (5 h) of the SigB-modulated strains were spotted on 
2% casein agar plates for 24 h at 37°C to detect extracellular protease production (Karlsson, 
2002). 
 
6. Bacterial adhesion assay to fibronectin 
The attachment properties of S. aureus strains RA1, TE1, and TE2 were measured using 
a previously described adhesion assay with polymethylmethacrylate (PMMA) coverslips 
coated in vitro with three different concentrations (0.5, 1, and 2 µg/ml) of purified human 
fibronectin (Fn) (Greene, 1995; Greene, 1996; Bisognano, 1997; Bisognano, 2000).  
Overnight cultures of S. aureus TE1, RA1, and TE2 were centrifuged and the pellets 
were suspended in 1 ml 0.9% NaCl. 20 µl each of suspended strains were mixed with 25 µl 
[methyl-3H]thymidine in 1ml MHB and the cultures incubated to late-logarithmic-phase (5 h) 
without shaking at 37°C. The bacterial cells were metabolically radiolabeled with [methyl-
3H]thymidine during the growth. When the influence of subinhibitory concentrations of 
ciprofloxacin on bacterial adhesion was tested, ciprofloxacin was added to 5-h cultures of 
quinolone-resistant strains of S. aureus at a concentration of 1/8 MIC of ciprofloxacin (4 
µg/ml). Thereafter, the radiolabeled bacterial cells were centrifuged for 10 min at 3000 rpm 
and  each strain was suspended in 1 ml 0.9% NaCl. 
Purified human fibronectin (Fn, Chemicon, Temecula, Calif.) was solubilized in 
phosphate-buffered saline (PBS) at 1 mg/ml and stored at –70°C. The concentration was 
measured spectrophotometrically using an extinction coefficient of  E280 = 1.28. 
Polymethylmethacrylate (PMMA) coverslips (1 × 1 cm) were cleaned with 100% 
alcohol for 5 min and sterilized by heating for 20 min at 120°C. To optimize adsorption of 
fibronectin from concentrations ranging from 0.5 to 2 µg/ml, the PMMA coverslips were 
precoated with gelatin (1 mg/ml) for 1 h at 37°C as previously described (Greene, 1995; 
Greene, 1996). After being rinsed in PBS, the coverslips were incubated in duplicate for 60 
min at 37°C with three different concentrations (0.5, 1, and 2 µg/ml) of fibronectin in PBS 
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and then rinsed in PBS as previously described (Greene, 1995; Greene, 1996). The previous 
study has showed that the PMMA surfaces were coated in a dose-dependent manner with 
fibronectin ranging from 88 to 296 ng per coverslip when radiolabeled fibronectin was used 
(Vaudaux, 1993; Bisognano, 1997). 
107 CFU of washed cultures of late-logarithmic phase thymidine-labelled cells were 
incubated with fibronectin-coated coverslips for 60 min at 37°C in PBS with 1 mM Ca2+ and 
0.5 mM Mg2+ supplemented with human albumin (5 mg/ml) which prevented nonspecific 
adhesion of S. aureus as previously described (Greene, 1995; Greene, 1996; Vaudaux, 1984). 
Gelatin-coated PMMA coverslips were used as controls of adhesion to fibronectin-coated 
surface (Greene, 1995; Greene, 1996). At the end of the attachment period, the fluids 
containing unbound bacteria were removed, the coverslips were rinsed, and radioactivity on 
the coverslips was counted by a β-scintillation counter as previously described (Vaudaux, 
1984). Bacterial adhesion data of the different strains whose cell-associated radioactivity and 
viable counts differed slightly (< 20%) were normalized as described (Vaudaux, 2002). 
Each experiment was performed three times. Relative changes in bacterial adhesion 
were expressed as the percent increase or decrease in attachment of strains TE1 and TE2 
compared to RA1 grown in ciprofloxacin-free medium, or between exposure and no exposure 
to ciprofloxacin for each strain. The results were expressed as the means + standard error of 
the means (SEM). The differences by strains TE1 and TE2 compared to RA1 and the 
differences between exposure and no exposure to ciprofloxacin in each strain were considered 
significant from each other when all increases or decreases accumulated for the three coating 
concentrations of fibronectin yielded P values of < 0.05 by paired t tests (Rosner, 1990). 
 
7. Quantification of FnBPs by flow cytometry 
The surface display of fibronectin-binding proteins by the SigB-modulated and 
quinolone-resistant (Q-R) strains of S. aureus was monitored by flow cytometry of 
formaldehyde-fixed late logarithmic-phase cells (5 h) as previously described (Vaudaux, 
2002; Francois, 2000; Hartford, 1997). 
 
7.1. Labeling fibronectin with FITC 
Purified human fibronectin (Fn) was solubilized in 0.2 M carbonate buffer (pH 9.2) at a 
concentration of 1 mg/ml and stored at –70°C. Fluorescein isothiocyanate (FITC) 1 mg was 
dissolved in 100 µl dimethyl sulfoxide (DMSO, 10 mg/ml), and protected from light. 
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Fibronectin was labelled with FITC by mixing 1 ml of the protein (1 mg/ml) with 10 µl of 
FITC for 2 h with rotating at room temperature. The reaction was stopped by adding 10 µl 
ethanolamine for 10 min.  
 
7.2. Purification of Fn-FITC 
Fn-FITC was purified by PD-10 column (Sephadex G-25, Pharmacia, Biotech) that was 
equilibrated with 15 ml PBS containing 1% human serum albumin (HSA) before use. Fn-
FITC (2 ml) was loaded onto the column, and the flowthrough collected in 1.5 ml eppendorf 
tubes. Fn-FITC was stored at – 20°C. 
 
7.3. Incubation of bacterial cells with FITC-Fn 
Approximately 108 CFU of each strain grown for 5 h at 37°C in 1 ml MHB were 
harvested by centrifugation at 4,000 rpm for 5 min. The bacterial cells were washed once with 
PBS containing 2.5% bovine serum albumin (BSA), and fixed with 0.5% (v/v) formaldehyde 
in PBS (pH 7.2) for 10 min at room temperature. After one wash with PBS-BSA, each 
bacterial cell was incubated with 200 µl of FITC-Fn in PBS-BSA for 60 min with rotating at 
room temperature. At the end of incubation, the bacterial cells were washed once with PBS-
BSA, suspended in 500 µl of BPS-BSA, and immediately assayed for fluorescence. 
 
7.4. Detection of fluorescence  
Flow cytometric analysis was performed on a Becton Dickinson FACSscan cytometer 
with 488 nm excitation light and the emission was measured through a 530/20 nm bandpass 
filter. In general, 10,000 cells were analysed with software WinMDI 2.8, and light scatter and 
the fluorescent signals were collected with logarithmic amplification. The threshold settings 
for non-specific fluorescence were obtained by using bacterial cells incubated without FITC-
Fn. The specificity of flow cytometry data was assessed by parallel analysis of the negative 
control strain DU5883, a mutant of 8325-4 simultaneously defective in expression of both 
FnBPA and FnBPB, and the positive control strain DU5883(pFNBB4) overexpressing 
FnBPB, respectively (Greene, 1995; Francois, 2000; Vaudaux, 2002). 
Relative changes in flow cytometry data were expressed as the percent increase or 
decrease in FITC-fibronectin binding by strains TE1 and TE2 compared to RA1 grown in 
ciprofloxacin-free medium, or between exposure and no exposure to ciprofloxacin for each 
strain. Each experiment was performed three times, and the results were expressed as mean 
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percent changes + standard errors of the means (SEM). The statistical significance of pairwise 
differences in FITC-fibronectin binding of isogenic strains differing in SigB functional levels 
or in ciprofloxacin exposure versus no exposure was evaluated by paired t tests, using P 
values of <0.05 with a two-tailed significance level (Rosner, 1990). 
 
8. Total RNA extraction 
Overnight cultures of the sigB null strain TE1, the rsbU sigB+ parent RA1, and the 
rsbU+ sigB+ strain TE2 were diluted 1/50 in 1 ml MHB and incubated to late exponential 
phase (5 h) at 37°C. When the influence of ciprofloxacin was tested, ciprofloxacin was added 
to the culture at 1/8 MIC of ciprofloxacin for each strain (4 µg/ml). At the end of incubation, 
the cultures were centrifuged for 5 min at 4,000 rpm. After removing supernatants carefully, 
the pellets were suspended in a mixture of 100% acetone and 100% ethanol (1:1) for 1 min on 
ice, and centrifuged for 5 min at 4,000 rpm at 4°C as previously described (Herbert, 2001; 
Renzoni, 2004). The treated cells were washed in N-Tris(hydroxymethyl)methyl-2-
aminoethanesulfonic acid (TES)-sucrose buffer (containing 20% sucrose), and lysed in 300 µl 
TES-sucrose buffer containing 200 µg /ml lysostaphin (20% [wt/vol] sucrose, 20 mM Tris 
[pH 7.6], 10 mM EDTA, 50 mM NaCl) for 30 min on ice. RNA extraction was performed 
using High Pure RNA Isolation kit (Roche Applied Science, Rotkreuz, Switzerland) 
according to the instruction of manufacturer. DNA was removed from the RNA preparations 
by treating twice with DNase I (Roche). The quantity and quality of RNA samples were 
analysed by the use of RNA NanoLab chip on the 2100 Bioanalyser (Agilent, Palo Alto, 
Calif.). 
 
9. Real-time RT-PCR 
The absence of contaminating DNA in RNA samples was verified by performing PCR 
using Platinum Quantitative PCR SuperMix-UDG (Invitrogen) in the TaqMan 7700 (Perkin-
Elmer Applied Biosystems, Foster City, Calif.) by using primers and probe of sigB gene 
(table 1). Only the RNA in which no DNA was detected by PCR was used afterwards. 
Steady-state mRNA levels were determined by quantitative real time RT-PCR (qRT-
PCR) by use of the one-step reverse transcriptase qPCR Master Mix Kit (Eurogentec, Seraing, 
Belgium) in the TaqMan 7700 as previously described (Vaudaux, 2002; Renzoni, 2004). All 
primers and probes were designed using PrimerExpress software (version 1.5; Applied 
Biosystems). The primers and probes, harboring a 5'FAM (6-carboxy-fluorescein) and a 
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3'TAMRA (6-carboxy-tetramethyl-rhodamine) were synthesized by Eurogentec (Seraing, 
Belgium). sarA and spA probes, harboring a 5'FAM and 3’minor groove binder, were 
synthesized by Applied Biosystem (Calif.). Table 1 shows the list of primers and probes used 
for this study. 
Reverse transcription (RT) and PCR were performed using primers and probes at 
concentrations of 0.2 and 0.1 µM, respectively. Primers and probes specific for the sigB and 
hla genes were used at a uniform concentration of 0.1 µM and those specific for sarA gene 
were used at a concentration of 0.05 µM.  
The total reaction volume was 15 µl. The mixture contained 0.3 µl primer and 0.3 µl 
probe, 7.5 µl of  2 × ThermoScript Reaction Mix buffer (final concentrations: 3 mM MgSO2, 
0.4 µM for each dNTP), 0.3 µl ROX passive reference component (for normalization of data 
as a passive reference), 0.3 µl ThermoScript Plus/ Platinum Taq  Enzyme Mix, 1.6 µl RNase-
free water and 4 ng total RNA (8 µl). For each reaction, all the reagents except RNA sample 
were put into the 96-well microplate, and RNA sample was put into each reaction as a final 
step. The microplate was centrifuged briefly to make sure that all the reagents were at the 
bottom of wells. 
RT-PCR was performed by 1 cycle of 30 min at 48°C and 10 min at 95°C for cDNA 
synthesis and pre-denaturation, and then PCR amplification of 40 cycles, using a two-step 
PCR cycling program of denaturation of 30 s at 95°C and annealing of 60 s at 60°C. After the 
last amplification cycle, samples were kept for final extension for 10 min at 72°C and 
immediately cooled to 4°C.  
Fluorescence emission was detected by the sequence detector ABI PrismTM 7700 and 
analyzed with Sequence Detector TM software (version 1.7; Applied Biosystems). The mRNA 
levels of all target genes extracted from the different strains grown with or without 
ciprofloxacin were normalized on the basis of their 16S rRNA levels, which were assayed in 
each round of qRT-PCR as internal controls as described previously (Vaudaux, 2002; 
Renzoni, 2004). Data were presented as means ± SEM of at least three experiments performed 
in triplicate. The statistical significance of strain-specific differences and differences of each 
strain grown in ciprofloxacin-containing compared to ciprofloxacin-free MHB in normalized 
threshold cycle (CT) values of each transcript were evaluated by paired t tests, and data were 
considered significant when P was <0.05 (Rosner, 1990). 
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Table 1. TaqMan primers and probes used in this study   
     
Gene Forward primer Reverse primer Probe (5'-3') 
16S 551F-GGCAAGCGTTATCCGGAATT 651R-GTTTCCAATGACCCTCCACG 573T-CCTACGCGCGCTTTACGCCCAa 
asp23 299F- GTTAACCACCTTTCATGTCTAAGATAC 390R- AAATTAACTTTCTCTGATGAAGTTGTTGA 333T- CTTCACGTGCAGCGATACCAGCAATTTa 
sigB  4862F-AAATTAGCAGTCATTAACCCATTCG 4962R- ACAAAATCCTTCTCTGCTGCC 
4900T- 
AAAAGGTGTGATTTATCCGCATCCACCAGa 
fnbA 268F-ACAAGTTGAAGTGGCACAGCC 341R-CCGCTACATCTGCTGATCTTGTC 
290T-
AGAACGGCATCAGAAAGTAAGCCACGTGa 
fnbB 803F-CACCGAAAACTGTGCAAGCA 889R-TCCTGTAGTTTCCTTATCAGCAACTT 
830T-
TAGAAACTTCGCGAGTTGATTTGCCATCGa 
RNAIII 367F-TTCACTGTGTCGATAATCCA 436R-TGATTTCAATGGCACAAGAT 
388T-
TTTACTAAGTCACCGATTGTTGAAATGAa 
agrA 34F-CAAAGAGAAAACATGGTTACCATTATTAA 135R-CTCAAGCACCTCATAAGGATTATCAG 83T-AAAAGCCTATGGAAATTGCCCTCGCAa 
sarA 17F-ACATGGCAATTACAAAAATCAATGAT 167R-TCTTTCTCTTTGTTTTCGCTGATG 45T-CTTTGAGTTGTTATCAATGGTb 
hla 337F- ATGAGTACTTTAACTTATGGATTCAACGG 437R- AGTGTATGACCAATCGAAACATTTG3 
385T- 
ACAGGAAAAATTGGCGGCCTTATTGGTa 
spA 1914F-CAGCAAACCATGCAGATGCTAA 1992R- ACAGTTGTACCGATGAATGGATTTT 1945T- AGCATTACCAGAAACTb 
sspA 5’GGTTAATTGCAGAAGGGAATGC 3’ 5’ ACTCTTTTAACAAATAAACACGTCGTAGA 3’ 5’ AAGCATGAGGATCACCGTGCGTAGC 3’ 
a 5'FAM and 3'TAMRA labeled. 
b5'FAM Minor Groove Binder and 3'dark quencher labeled.  
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10. Northern blotting  
10.1. Agarose/formaldehyde gel electrophoresis 
All the equipments were autoclaved before using. All solutions were prepared using 
0.1% diethylpyrocarbonate (DEPC) water to avoid RNase contamination. Total RNA was 
extracted as described in total RNA extraction. The concentration of RNA was measured by 
the RNA NanoLab chip on the 2100 bioanalyzer (Agilent, Palo Alto, Calif.). Sixteen µg of 
total RNA of each sample and a 6583-bp RNA marker (Promega) mixed with formaldehyde 
loading buffer were separated by a 1.8% agarose-0.66 M formaldehyde gel in 1 × 3-N-
morpholine propane sulfonic acid (MOPS) running buffer for 3 h at room temperature. The 
voltage for electrophoresis was 90 V. MOPS buffer was prepared by 20 mM MOPS, 10 mM 
sodium acetate, 2 mM ethylenediaminetetraacetic acid (EDTA, pH 8.0) and 0.1% DEPC 
water. The solution was adjusted to the final pH 7.0 using 2 M NaOH. The intensities of the 
23S and 16S rRNA bands suggested equivalent RNA loading in all samples using ethidium 
bromide and UV visualization.  
 
10.2. Blotting RNA from gel onto membrane 
Blotting of RNA from gel onto positively charged nylon membranes (hybond-N+, 
Amersham, Switzerland) was performed by two methods. Up capillary transfer was 
performed using Whatman 3 MM filter paper wick method as essentially described in the 
protocol (Brown, 1997). The transfer was done in buffer 20 × SSC (1 × SSC was 0.15 M 
NaCl plus 0.015 M sodium citrate) for overnight at room temperature. Another transfer 
method was using electroblotting system (Bio-Rad, Mini Trans-Blot electrophoretic transfer 
cell). The transfer was done in 1 × Tris-Borate-EDTA (TBE) buffer at 400 AM for 3 h at 
room temperature in accordance with the protocol (Chory, 1997). The blotted membranes 
from both methods were fixed by UV-crosslinking (Spectro Linker, XL-100) for 1 min. 
 
10.3. Probe labelling 
The PCR fragments for probes were generated by PCR amplification using an Expand 
High Fidelity PCR System (Roche) in trio-thermoblock (Biometra). The template DNA was 
generated by using a chromosomal DNA of NCTC8325 isolated with chromosomal DNA 
isolation kit (Qiagen, Switzerland). The primers of 16S ribosomal RNA, sigB, sarA, and 
RNAIII that were used to generate probe fragments are listed in table 2. The PCR products 
were purified by a gel extraction kit (Qiaquick, Qiagen, Switzerland). 194-bp sigB, 290-bp 
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sarA, and 1040-bp 16S rRNA fragments were labelled with [α-32P]dCTP by use of a Prime-it 
Random Primer Labeling kit (Stratagene) according to the protocol of manufacture, and 
purified by use of Sephadex G-50 DNA columns (Pharmacia, Biotech) in 1 × TE buffer. 439-
bp RNAIII probe fragment was labelled with digoxigenin (DIG)-dUTP, by use of a Dig High 
Prime DNA Labelling and Detection Starter kit II (Roche). The labelling efficiency for 
RNAIII was determined by semi-quantitative determination with the control labelled DNA 
(supplied in the kit). 
 
10.4. Hybridization and detection 
The blotted membranes for sigB, sarA and 16S rRNA were pre-hybridized with 200 µl 
Rapid-Hyb Buffer (Amersham) for 2 h at 65°C by rotating, and then hybridized with the same 
Rapid-Hyb Buffer containing 200 µl sigB, sarA or 16S rRNA probe (0.125 µg [α-32P] dCTP 
for each probe) for overnight at 65°C by rotating. The hybridized membrane were strictly 
washed first with 2 × SSC-0.1% sodium dodecyl sulfate (SDS) for 20 min at room 
temperature, second with 1 × SSC-0.1% SDS for 15 min at 65°C, and finally with 0.5 × SSC-
0.1% SDS for 15 min at 65°C. The humid membranes were sealed in a plastic paper, and 
exposed to the film (Kodak-Omat AR Film) for overnight.  
The blotted membrane for RNAIII was pre-hybridized in 25 ml dig-easy-hyb buffer 
(Dig High Prime DNA labelling and Detection Starter kit II, Roche) for 2 h at 50°C with 
shaking 60 rpm, and hybridized in the same dig-easy-hyb buffer containing 25 ng/ml RNAIII 
DIG-labelled probe for overnight at 50°C with shaking 60 rpm. The hybridized membrane 
was strictly washed first with 2 × SSC-0.1% SDS for 15 min at room temperature with 
shaking 60 rpm, second with 1 × SSC-0.1% SDS for 15 min at 37°C, and finally twice with 
0.5 × SSC-0.1% SDS for 15 min at 50°C with shaking 60 rpm. After washing briefly with 1 × 
washing buffer (supplied in the kit) for 5 min, the membrane was incubated with block 
solution for 60 min, and antibody solution (anti-digoxigenin-AP, 75 mU/ml) for 60 min at 
room temperature. Following washing the membrane with 1 × washing buffer two times for 
15 min, and equilibrated with 1 × detection buffer for 5 min at the room temperature, the 
membrane was carefully covered with 1 ml chemiluminescent substrate for alkaline 
phosphatase (CSPD, ready to use) and incubated for 5 min at room temperature and then for 
10 min at 37°C. The membrane was immediately exposed to the film (Kodak Biomax MR 
film) for 20 – 30 min.  
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Table 2. Specific primers used to generate the probes for Northern blotting. 
 
genes  Up primer Down primer 
16S rRNA 5'- GGTAGAGCCTTCCCCTTCGG-3' 5'-CCGGCAGTCAAGTTAGAGTGC-3' 
sigB 5'-GATATTATGGGGCAACAAGATGACC-3' 5'-GCCGTTCTCTGAAGTCGTGATACAT-3' 
sarA 5 '-ATGATTGCTTTGAGTTGTTATCAAT-3' 5'-ACTCAATAATGATTCGATTTTTTTA-3' 
RNAIII 5'-GTCATTATACGATTTAGTAC-3' 5'-GGTTATTAAGTTGGGATG-3'. 
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C. RESULTS 
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1. MICs of ciprofloxacin for the Q-R strains  
The MICs of ciprofloxacin for sigB null strain TE1, rsbU sigB+ parent RA1, and rsbU+ 
sigB+ strain TE2 were identical: 32 µg/ml. We decided to use 1/8 MIC (4 µg/ml) of 
ciprofloxacin in all the experiments when ciprofloxacin influence was tested, since this sub-
MIC of ciprofloxacin was shown previously to optimally promote FnBPs without 
significantly affecting bacterial growth rate (Bisognano, 2000) 
 
2. Phenotypic charateristics of SigB-modulated strains 
(1) Pigmentation 
 
The orange-yellow pigment staphyloxanthin has been shown to be positively regulated 
by SigB activity. ∆rsbUVWsigB mutants of genetically distinct wild-type S. aureus strains 
COL and Newman were reported to be almost unpigmented, whereas a rsbU-complemented 
strain of NCTC8325 derivative BB255 has orange pigment (Kullik, 1998; Giachino, 2001). 
The pigmentation of three SigB-modified strains was clearly influenced by their SigB 
activity: sigB null strain TE1 had no colour, rsbU sigB+ parent RA1 had a pale yellow colour, 
and rsbU+ sigB+ strain TE2 had a bright orange colour (figure 1).  
 
(2) Hemolysin activity  
Alpha-hemolysin activity has been shown to be negatively regulated by SigB activity, 
since inactivation of sigB leads to upregulation of hla (Cheung, 1999). Hemolysin activities 
of the SigB-modified strains TE1, RA1, and TE2 were recorded by examining the lysed zones 
around spotted colonies grown on sheep blood agar (SBA) (figure 2). After incubation for 24 
h at 37°C on SBA, the sigB null strain TE1 and rsbU sigB+ parent RA1 produced clear zones 
of complete hemolysis (average 12 mm) around the bacterial colonies, indicating production 
Figure 1. Production of pigmentation: sigB null strain TE1, no 
colour; rsbU sigB + parent RA1, pale yellow; rsbU + sigB + strain
TE2, bright orange.
TE2
RA1
TE1
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of α-toxin, while much smaller clear hemolytic zones (7 mm) were seen around colonies of 
rsbU+ sigB+ strain TE2. The hot-cold hemolysis reflecting β-toxin and yields halo effects 
around the clear zones. The exact sizes of hemolytic zones specifically due to β-toxin was 
difficult to estimate for the different SigB-modulated strains, but strain TE2 had much smaller 
halo zones than strain TE1 and RA1 (figure 2). ATCC (American Type Culture Collection) 
25923 was used as a positive control strain of β-toxin (figure 2).  
 
 (3) Protease activity 
Protease activity has been shown to be indirectly suppressed by SigB functional level, 
since expression of the protease is repressed by SigB-dependent SarA (Karlsson, 2002). 
Protease activities of the SigB-modulated strains TE1, RA1, and TE2 were recorded by 
examining the lysed zones around spotted colonies grown on casein agar (figure 3). After 
incubation for 24 h at 37°C, the sigB null strain TE1 and rsbU sigB+ parent RA1 produced 
clear zones (average 10 mm) around the bacterial colonies, indicating production of protease, 
while no zones were seen around colonies of rsbU+ sigB+ strain TE2 (figure 3). The results 
confirmed the previous study that SigB activity negatively regulates protease production 
(Karlsson, 2002). 
 
TE2
RA1
TE1 Figure 3. Protease activities of sigB null strain TE1, 
rsbU sigB + parent RA1, and  rsbU + sigB + strain TE2 
on casein agar plate. 
Figure 2. Hemolysins of strains TE1, RA1, and 
TE2 on SBA. The clear zones (short arrow) 
around bacterial colonies were produced by α-
toxin. The halo effects (long arrow) around the 
clear zones were produced by β-toxin. 
ATCC25923 was used as a positive control strain 
of β-toxin.
RA1
TE1 TE2
ATCC
25923
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3. Modulation of S. aureus adhesion on fibronectin-coated surfaces by SigB 
levels and ciprofloxacin exposure 
 
Strains grown in ciprofloxacin-free medium 
Following growth in ciprofloxacin-free medium, the attachment of sigB null strain TE1, 
averaged over the three fibronectin coating concentrations, was significantly lower (29 %, P < 
0.01) than that of its rsbU sigB+ parent RA1. In contrast, the average adhesion of rsbU+ sigB+ 
strain TE2 increased significantly (31 %, P < 0.01) compared to its parent RA1 (figure 4). 
Thus, the respective adhesion values of strains TE1, RA1, and TE2, increased as a function of 
the predicted increase in their SigB functional activity. 
 
Effect of ciprofloxacin 
In contrast, upregulation of bacterial attachment by growth in the presence of 1/8 MIC 
of ciprofloxacin (4 µg/ml) in the different strains was not significantly influenced by 
modulation of their SigB functional levels. The average ciprofloxacin-promoted increase in 
adhesion, over the three fibronectin coating concentrations, was significant (P < 0.01) and 
almost equivalent for sigB null strain TE1 (62 %), rsbU sigB+ parent RA1 (62 %), and rsbU+ 
sigB+ strain TE2 (77 %), respectively (figure 4).  
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Figure 4. (up) Dose-response curves of adhesion to fibronectin-coated coverslips of sigB null strains TE1, rsbU 
sigB+ parent RA1, and rsbU+ sigB+ strain TE2 grown either in the absence or presence of 4 µg/ml (1/8 MIC) of 
ciprofloxacin (CFX), expressed as CFU numbers of adherent S. aureus on coverslips coated with fibronectin.  
(down) Percent changes in average adhesion to fibronectin-coated coverslips of TE1 and TE2, grown either in 
the absence or presence of 4 µg/ml (1/8 MIC) of ciprofloxacin (CFX), compared to RA1 adhesion in 
ciprofloxacin-free medium. Values represent means + SEMs (error bars) of individual adhesion data cumulated 
over the three fibronectin coating concentrations, in three experiments.  
*, results significantly different (P < 0.05) for each strain grown in ciprofloxacin-containing MHB from those in 
ciprofloxacin free MHB.  
**, results significantly different (P < 0.05) from those of strain RA1 grown in ciprofloxacin-free medium. 
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4. Effect of S. aureus binding to FITC-fibronectin by SigB levels and 
ciprofloxacin exposure 
Surface display of FnBPs including FnBPA and FnBPB in the SigB-modified strains 
was analyzed by flow cytometry. 
 
Strains grown in ciprofloxacin-free medium 
Following growth in the ciprofloxacin-free medium, the binding of FITC-labelled 
fibronectin by rsbU+ sigB+ strain TE2 increased significantly (127 %, P < 0.05) whereas the 
binding of sigB null strain TE1 decreased significantly (38 %, P < 0.05) compared to their 
rsbU sigB+ parent RA1 (figure 5). Thus, the respective binding values of FITC-labelled 
fibronectin by the SigB-modulated strains TE1, RA1, and TE2, increased as a function of the 
predicted increase in their SigB functional activity. 
 
Effect of ciprofloxacin 
After growth in the ciprofloxacin-containing medium, the binding of FITC-fibronectin 
by three SigB-modulated strains was significantly (P < 0.05) higher than that of the strains 
grown in the ciprofloxacin-free medium (figure 5). The relative fluorescent levels of the sigB 
null strain TE1, rsbU sigB+ parent RA1, and rsbU+ sigB+ strain TE2 increased 80 %, 105 %, 
and 132 %, respectively, regardless of their SigB functional levels. 
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Figure 5. Binding of FITC-labelled fibronectin by sigB null strain TE1, rsbU sigB+ parent RA1, and rsbU+ 
sigB+ strain TE2 grown either in the absence or presence of 4 µg/ml (1/8 MIC) of ciprofloxacin (CFX), 
expressed as percentages of rsbU sigB+ parent RA1 fluorescent level in ciprofloxacin-free medium performed at 
least three experiments. DU5883 (pFNBB4) and DU5883 were positive and negative controls, respectively.  
*, results significantly different (P < 0.05) for each strain grown in ciprofloxacin-containing MHB from those in 
ciprofloxacin-free MHB.  
**, results significantly different (P < 0.05) from those of strain RA1 grown in ciprofloxacin-free medium.  
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5. Assessment of sigB transcripts and SigB functional levels in the SigB-
modulated strains  
 
Strains grown in ciprofloxacin-free medium 
The sigB transcript levels detected by quantitative RT-PCR were strongly (13.8-fold) 
elevated in rsbU+ sigB+ strain TE2 compared to its rsbU sigB+ parent RA1 (figure 6, up).  
Unexpectedly, sigB transcript levels recorded in sigB null strain TE1 were found 
equivalent to those assayed in RA1, despite the presence of the transposon in the sigB gene. 
Because of sigB primers and probe selected for RT-PCR were located shortly after Tn551 
insertion (figure 6, down right), I tried to detect the exact size of transcripts of TE1 originated 
from PA and PB compared to those in strains RA1 and TE2 by Northern affinity blotting. 
Northern blotting showed the presence in TE1 of two much higher molecular sigB transcripts, 
7.6-kb rsbUVWsigB (including whole Tn551) from promoter A and 7.0-kb rsbVWsigB 
(including whole Tn551) from promoter B, compared to those recorded in TE2 or RA1 
(figure 6, down). The larger size of sigB transcripts in sigB null strain TE1 reflects the 
presence of Tn551-encoded elements (5.1 kb). Besides the presence of a strong 1.9-kb sigB 
transcript in RA1 and TE2, another weaker 2.5-kb transcript was present on the original 
Northern blotting film both in TE2 and RA1, but was too weak in RA1 to be seen in the 
printed figure (figure 6, down). 
Transcript levels of the alkaline-shock protein 23 (asp23) gene which is frequently used 
as a marker for SigB functional activity showed a 10.3-fold increase in rsbU+ sigB+ strain 
TE2 compared to its rsbU sigB+ parent RA1. A striking finding was the 100-fold decrease in 
the asp23 transcript levels recorded in sigB null strain TE1 compared to RA1, providing 
indirect evidence for a strong reduction of SigB functional levels TE1 compared to RA1 
(figure 6, up). 
 
Ciprofloxacin effect 
Ciprofloxacin exposure led to a significant (P < 0.05) increase in sigB transcript levels 
of strain RA1, but not TE2. At the opposite, ciprofloxacin exposure led to significantly (P < 
0.05) increased asp23 levels in strain TE2, but not RA1 (figure 6, up). 
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Figure 6. (up). Steady state mRNA levels of sigB (left panel) and asp23 (right panel) genes of sigB null strain 
TE1 and rsbU+ sigB+ strain TE2, grown in the absence or presence of 4 µg/ml (1/8 MIC) of ciprofloxacin 
(CFX), expressed as percentages of those of rsbU sigB+ parent RA1 grown in ciprofloxacin-free medium.  
mRNA levels were determined by real-time RT-PCR and normalized on the basis of their 16S rRNA levels. 
Values are the means + SEMs of at least three experiments performed in triplicate.  
*, results significantly different (P < 0.05) for each strain grown in ciprofloxacin-containing compared to 
ciprofloxacin-free MHB.  
**, results significantly different (P < 0.05) from those of strain RA1 grown in ciprofloxacin-free medium.  
asp23 transcripts levels of sigB null strain TE1 were too small to be visualized (see text).  
(down). Northern blot (left) of sigB transcripts in sigB null strain TE1, rsbU+ sigB+ strain TE2, and rsbU sigB+ 
parent RA1. 16 µg total RNA isolated from strains grown for 5 h was loaded in each lane. (right) Schematic 
representation of sigB operon in S. aureus. The primers and probe used for RT-PCR and the probe used for 
Northern blotting, open reading frames, putative promoters, and the transcription terminal are indicated.  
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6. Upregulation of fnbA and fnbB transcripts by SigB levels and 
ciprofloxacin exposure 
Since quantitative adhesion and surface display of FnBPs were upregulated by 
restoration of functional SigB activity as well as by subinhibitory levels of ciprofloxacin, we 
assayed the steady-state fnbA and fnbB mRNA levels of each SigB-modulated strain by real 
time quantitative RT-PCR (qRT-PCR). 
 
Strains grown in ciprofloxacin-free medium 
After growth in ciprofloxacin-free medium, fnbA mRNA levels were equivalent in sigB 
null strain TE1 and rsbU sigB+ parent RA1, but significantly (P < 0.01) increased by 4-fold 
from RA1 to rsbU+ sigB+ strain TE2. In similar conditions, fnbB mRNA levels were also 
equivalent in strains TE1 and RA1, but sharply (P < 0.01) increased by 12-fold from RA1 to 
TE2 (figure 7). 
 
Effect of ciprofloxacin 
In contrast, the relative increases in fnbA and fnbB transcript levels triggered in the 
different strains by growth in the presence of 4 µg/ml of ciprofloxacin were not correlated 
with their respective SigB functional levels. The ciprofloxacin-mediated increases in fnbB 
transcripts in sigB null strain TE1, rsbU sigB+ parent RA1, and rsbU+ sigB+ strain TE2 were 
5.0-fold, 5.8-fold, and 2.8-fold, respectively, being significantly (P < 0.01) greater than those 
when they grown in the absence of ciprofloxacin. The fnbA transcripts increased significantly 
(P < 0.01) 2.5-fold, 1.9-fold, and 1.7-fold in sigB null strain TE1, rsbU sigB+ parent RA1, and 
rsbU+ sigB+ strain TE2, respectively, when they grown in the presence of ciprofloxacin 
compared to those in the absence of ciprofloxacin (figure 7). 
Steady-state fnbB mRNA levels increased very sharply (about 35 fold) from sigB null 
strain TE1 when grown in the ciprofloxacin-free medium to rsbU+ sigB+ strain TE2 when 
grown in the ciprofloxacin-containing medium (figure 7). 
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Figure 7. Steady-state levels of fnbA (left panel) and fnbB (right panel) transcripts of strains sigB null strain TE1 
and rsbU+ sigB+ strain TE2, grown in the absence or presence of 4 µg/ml (1/8 MIC) of ciprofloxacin (CFX), 
expressed as percentages of those of rsbU sigB+ parent RA1 grown in ciprofloxacin-free medium.  
mRNA levels were determined by real-time RT-PCR and normalized on the basis of their 16S rRNA levels. 
Values represent the means + SEMs of at least three experiments performed in triplicate. 
*, results significantly different (P < 0.05) for each strain grown in ciprofloxacin-containing compared to 
ciprofloxacin-free MHB. 
**, results significantly different (P < 0.05) from those of parent strain RA1 grown in ciprofloxacin-free medium.  
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7. Influence of SigB levels and ciprofloxacin exposure on agr transcripts 
levels 
The global regulator agr has been shown to play an essential role in down-regulating the 
synthesis of cell-surface adhesions such as FnBPs and protein A (Saravia-Otten, 1997; 
Dunman, 2001; Cheung, 2004). To detect any potential change in agr activity that might 
contribute to either the SigB-mediated or/and the ciprofloxacin-triggered upregulation of fnb 
genes, we assayed agr RNAII and RNAIII levels in sigB null strain TE1, rsbU sigB+ parent 
RA1, and rsbU+ sigB+ strain TE2. 
 
Strains grown in ciprofloxacin-free medium  
RNAII levels of three strains grown in ciprofloxacin-free medium were almost 
equivalent in TE1 and RA1, but showed a slight but not significant decrease in TE2 compared 
to RA1 and TE1. RNAIII levels were also similar in strains TE1 and RA1 grown in 
ciprofloxacin-free medium, but showed a significant 79% decline in TE2 compared to RA1, 
as confirmed by Northern blotting analysis (figure 8). 
 
Effect of ciprofloxacin 
Ciprofloxacin exposure led to a significant (P < 0.05) but slight (< 2-fold) increase in 
RNAII levels for strains RA1 and TE2, but not TE1. At the opposite, ciprofloxacin exposure 
led to significantly (P < 0.01) increased RNAIII levels in strain TE2 only, but not TE1 or 
RA1 (figure 8). 
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Figure 8. (up) Steady-state levels of RNAII and RNAIII of sigB null strain TE1 and rsbU+ sigB+ strain TE2, 
grown in the absence or presence of 4 µg/ml (1/8 MIC) of ciprofloxacin (CFX), expressed as percentages of 
those of rsbU sigB+ parent RA1 grown in ciprofloxacin-free medium.  
mRNA levels were determined by real-time RT-PCR and normalized on the basis of their 16S rRNA levels. 
Values represent the means + SEM of three experiments performed in triplicate. 
*, results significantly different (P < 0.05) for each strain grown in ciprofloxacin-containing compared to 
ciprofloxacin-free MHB.  
**, results significantly different (P < 0.05) from those of strain RA1 grown in ciprofloxacin-free medium.  
(down) Northern blotting of RNAIII in strains TE1, RA1, and TE2. 16S rRNA was used as a RNA loading 
control. 16 µg total RNA isolated from strains grown to 5 h was loaded in each lane. 
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8. Impact of SigB levels and ciprofloxacin exposure on sarA transcripts 
levels  
We next evaluated whether the global regulator sarA could contribute to either the 
SigB-mediated or/and the ciprofloxacin-triggered upregulation of fnb genes. 
 
Strains grown in ciprofloxacin-free medium  
While the overall sarA steady-state mRNA levels assayed by qRT-PCR of three strains 
grown in ciprofloxacin-free medium were equivalent in sigB null strain TE1 and rsbU sigB+ 
parent RA1, they showed a slight (53%) but significant (P < 0.01) increase in rsbU+ sigB+ 
strain TE2 compared to its parent RA1 (figure 9, up).  
Since the sarA locus is composed of three overlapping transcripts of 0.58, 0.84, and 
1.15 kb, initiated from the P1, P3, and P2 promoters, respectively, I also performed Northern 
blotting analysis to analyze the SigB-dependent P3-driven transcript. Figure 9 (down) 
demonstrates a stepwise increase in the SigB-dependent P3-driven transcript from strain sigB 
null strain TE1 to parent RA1, and from RA1 to rsbU+ sigB+ strain TE2, as a function of the 
predicted increase in their SigB functional activity, and as expected from previous studies 
(Bischoff, 2004; Bischoff, 2001; Deora, 1997; Gertz, 2000; Manna, 1998).  
 
Effect of ciprofloxacin 
Ciprofloxacin exposure led to a significant (P < 0.05) ca. 2-fold increase in sarA 
transcript levels in all strains TE1, RA1, and TE2 (figure 9, up). 
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Figure 9. (up) Steady-state levels of sarA transcripts of sigB null strain TE1 and rsbU+ sigB+ strain TE2, grown 
in the absence or presence of 4 µg/ml (1/8 MIC) of ciprofloxacin (CFX), expressed as percentages of those of 
rsbU sigB+ parent RA1 grown in ciprofloxacin-free medium.  
mRNA levels were determined by real-time RT-PCR and normalized on the basis of their 16S rRNA levels. 
Values represent the means + SEMs of at least three experiments performed in triplicate.  
*, results significantly different (P < 0.05) for each strain grown in ciprofloxacin-containing compared to 
ciprofloxacin-free MHB.  
**, results significantly different (P < 0.05) from those of strain RA1 grown in ciprofloxacin-free medium. 
(down) Northern blotting (left) of sarA transcripts in sigB null strain TE1, rsbU sigB+ parent RA1, and rsbU+ 
sigB+ strain TE2. 16S rRNA probe was used as a RNA loading control. 16 µg of total RNA isolated from strains 
grown for 5 h was loaded in each lane. (right) Schematic presentation of sarA locus. The sarA probe used for 
Northern analysis, promoters, and the transcripts are indicated. 
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9. Impact of SigB levels and ciprofloxacin exposure on hla and spa 
transcript levels  
Since previous reports demonstrated a strong impact of agr, sarA, and sigB regulons on 
the expression of α-hemolysin and protein A (Arvidson, 2001; Bischoff, 2004; Cheung, 2004; 
Norvick, 2003), we assayed hla and spa transcript levels of these target genes by qRT-PCR in 
the SigB-modulated strains grown in the absence or presence of ciprofloxacin. 
 
Strains grown in ciprofloxacin-free medium  
Striking differences were found in hla and spa transcript levels of rsbU+ sigB+ strain 
TE2 compared to sigB null strain TE1 and rsbU sigB+ parent RA1. In TE2, hla transcript 
levels were < 10% of the nearly equivalent levels recorded in TE1 and RA1 (figure 10, left). 
These strain-specific differences in hla mRNA levels likely accounted for the strongly 
reduced hemolytic zones produced on sheep blood agar by strain TE2 compared to RA1 and 
TE1 (figure 2).  
An inverse situation was found for spa transcript levels that were increased by > 25-fold 
in TE2 compared to the low, but nearly equivalent levels recorded in TE1 and RA1 (figure 
10, right). 
 
Effect of ciprofloxacin 
While ciprofloxacin exposure led to a significant increase in hla transcript levels of 
strain TE2, but not RA1 and TE1, an inverse situation was seen with spa transcripts whose 
levels were elevated in strains RA1 and TE1, but not TE2. 
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Figure 10. Steady-state levels of hla and spa transcripts of sigB null strain TE1 and rsbU+ sigB+ strain TE2, 
grown in the absence or presence of 4 µg/ml (1/8 MIC) of ciprofloxacin (CFX), expressed as percentages of 
those of rsbU sigB+ parent RA1 grown in ciprofloxacin-free medium.  
mRNA levels were determined by real-time RT-PCR and normalized on the basis of their 16S rRNA levels. 
Values represent the means + SEMs of three experiments performed in triplicate.  
*, results significantly different (P < 0.05) for each strain grown in ciprofloxacin-containing compared to 
ciprofloxacin-free MHB.  
**, results significantly different (P < 0.05) from those of strain RA1 grown in ciprofloxacin-free medium. 
 
0
500
1000
1500
2000
2500
3000
spA
RA1TE1 TE2
-CFX
+CFX
* *
**
0
50
100
150
200
250
300
350
RA1TE1 TE2
*
hla
-CFX
+CFX
**m
R
N
A
 le
ve
ls
 (%
)
m
R
N
A
 le
ve
ls
 (%
)
m
R
N
A
 le
ve
ls
 (%
)
m
R
N
A
 le
ve
ls
 (%
)
 77
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D. DISCUSSION AND CONCLUSION 
 78
 
Growing evidence suggests that expression and surface display of FnBPs in S. aureus 
are regulated by a complex network of global regulators, transcription factors, and stress 
response pathways (Bischoff, 2004; Bischoff, 2001b; Bisognano, 2000; Bisognano, 2004; 
Blevins, 2002; Huesca, 2002; Karlsson, 2001; Saravia-Otten, 1997; Savolainen, 2001; 
Vaudaux, 2002; Vaudaux, 1998; Wolz, 2000; Xiong, 2004). Besides the previously reported 
growth-phase and quorum sensing-controlled effects of agr and sarA regulons on 
transcription of fnb genes and/or FnBP surface display (Blevins, 2002; Saravia-Otten, 1997; 
Wolz, 2000; Xiong, 2004), a variety of environmental or/and stressful conditions may also 
alter expression of fibronectin adhesins. These diverse situations include switching to small-
colony variant phenotypes (Vaudaux, 2002), acquisition of methicillin resistance (Rice, 2001; 
Savolainen, 2001; Vaudaux, 1998), emergence of teicoplanin resistance (Renzoni, 2004), or 
exposure of fluoroquinolone-resistant S. aureus to subinhibitory levels of ciprofloxacin 
(Bisognano, 1997; Bisognano, 2000; Bisognano, 2004). Except for the indirect impact of the 
methicillin resistance element, which does not affect fnb transcription but is believed to 
interfere with FnBP surface display via production of the pls surface protein (Huesca, 2002; 
Savolainen, 2001), all other conditions mentioned above were shown to regulate fnb 
transcription (Bisognano, 1997; Bisognano, 2000; Bisognano, 2004; Vaudaux, 2002). The 
upregulation of FnBP expression by specific environmental and stressful stimuli including 
fluoroquinolone exposure may play a significant role in promoting S. aureus attachment and 
colonization of host tissues or implanted biomaterials (Vaudaux, 2000).  
The production of isogenic derivatives of the fluoroquinolone-resistant grlA gyrA 
double mutant strain RA1 of S. aureus, displaying widely different levels of SigB activity, 
allowed to explore the potential interaction of the SigB-mediated and ciprofloxacin-triggered 
pathways. Combination of transcriptional and phenotypic assays provided indirect though 
consistent evidence that the SigB-mediated and ciprofloxacin-triggered responses involved 
separate regulatory networks, whose characterization is still incomplete.  
We recently reported the contribution of a RecA-LexA pathway on the ciprofloxacin-
triggered induction of fibronectin binding via selective upregulation of the fnbB gene which 
did not require any functional agr or sarA activities (Bisognano, 2004). This study extends 
those previous findings by showing that the SigB functional activity does not interfere with 
the ciprofloxacin-triggered transcriptional and phenotypic responses. While the strong 
induction of the fnbB gene by a sub-MIC level of ciprofloxacin was confirmed in the SigB-
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modulated derivatives of strain RA1, the fnbA gene was also induced though to a much lower 
extent. The ciprofloxacin-triggered fnbA induction may possibly result from the longer 
exposure of each strain with ciprofloxacin in this study compared to the shorter 20-min 
exposure in the previous report which failed to significantly induce fnbA (Bisognano, 2004). 
Further studies are required to elucidate the molecular basis of the differential ciprofloxacin-
triggered fnbA versus fnbB upregulation. 
In contrast to the ciprofloxacin-triggered responses, those promoted by genetic 
modulation of SigB functional activity appear more complex at both transcriptional and 
phenotypic levels, as supported by a recent microarray-based analysis of the S. aureus SigB 
regulon (Bischoff, 2004). A previous report also showed that GP268, a strain carrying an 
intact sigB operon as the rsbU+ sigB+ strain TE2, had a higher fibronectin surface display than 
NCTC8325 derivative BB255 and its ∆rsbUVWsigB mutant (Bischoff, 2001). In this study, 
the higher fnbA and fnbB mRNA levels that were detected in strain TE2 compared to the sigB 
null strain TE1 and rsbU  sigB+ parent RA1 were, at least partly, confirm a recent report 
showing a higher level of fnbA in a SigB-restored strain by Northern blotting (Nair, 2003).  
In our experimental conditions, similar transcript levels were recorded for either fnbA or 
fnbB when comparing the sigB null TE1 with its rsbU sigB+ parent RA1. In contrast, there 
was a sharp though disproportionate increase in fnbB versus fnbA transcript levels assessed in 
the rsbU+ -restored strain TE2 compared to its rsbU sigB+ parent RA1. The fnbA and fnbB 
transcriptional dose-response data contrasted with the smoother increase in FnBP surface 
display from strain TE1 to TE2 via RA1 as recorded by bacterial adhesion and flow 
cytometry assays. The molecular basis of these contrasted data is not understood and its 
elucidation will require improved understanding of the SigB-controlled pathway and its 
interactions with other regulatory networks controlling expression of fibronectin adhesins. 
Since expression of extracellular proteases was shown to be downregulated by high SigB and 
sarA functional levels (Karlsson, 2002) and upregulated by agr (Novick, 2003), we assayed in 
our set of SigB-modulated strains the levels of extracellular proteases that could potentially 
alter the half-life of surface-exposed FnBPs (Karlsson, 2001, McGavin, 1997). The levels of 
proteolytic activity recorded on supernatants from 5-h cultures were too low to allow 
assessment of strain-specific differences. While qRT-PCR data indicated a decreased 
expression of the V8 protease gene sspA (data not shown) in the SigB-restored strain TE2 
compared to non-restored isogenic derivatives, the extracellular protease release seems to be 
too marginal to play a major role in 5-h cultures. Previous reports have shown that production 
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of proteases mainly occurs during the late exponential and postexponential phases of growth 
(Horsburgh, 2002; Karlsson, 2001; Karlsson, 2002). Thus, our initial hypothesis that strain-
dependent differences in production and extracellular release of proteases may account for the 
lack of correlation between fnb transcription and fibronectin adhesion was not supported by 
our experimental data. This discrepancy between fnb transcript levels and fibronectin binding, 
which was also previously reported (Saravia-Otten, 1997), may possibly results from 
differences in fnbA or/and fnbB mRNA decay between strain TE2 and RA1 or TE2, or from 
saturating amounts of cell wall-anchored FnBP molecules that may be displayed on bacterial 
cell surfaces.  
The potential contribution of the major global regulators agr and sarA to increased 
levels of both fnbB transcripts in the rsbU+ -restored strain TE2 compared to RA1 and TE1 
was also evaluated. It should be emphasized that transcript levels from global regulators and 
their putative target genes from 5-h cultures grown without shaking cannot be directly 
compared with those from cultures grown with rotatory shaking whose growth rates and final 
biomass are much higher. In contrast to agr RNAII levels that were equivalent in all three 
strains, RNAIII levels were reduced by less than one order of magnitude in strain TE2 
compared to RA1 and TE1, thus confirming the previously reported downregulation of the 
agr response regulator in strains displaying fully functional levels of SigB compared to their 
SigB-defective derivatives (Bischoff, 2001; Horsburgh, 2002). While the decreased RNAIII 
levels in strain TE2 compared to RA1 and TE1 may explain, at least in part (Dunman, 2001), 
the changes recorded on hla and spa transcript levels of the former compared to the latter 
strains, the molecular details of the RNAIII-mediated downregulation of each fnb gene are 
still unknown. Since no selective effect of RNAIII on fnbB compared to fnbA transcript levels 
has yet been reported, it is likely that other global regulatory systems or transcription factors 
may play a significant role in this complex regulatory process (Arvidson, 2001; Cheung, 
2004; Norvick, 2003).  
The impact of SigB functional levels on activities of the sarA regulon is controversial. 
While some studies indicate a SigB-promoted upregulation of sarA transcription (Bischoff, 
2004; Bischoff, 2001a; Gertz, 1999) and translation (Gertz, 2000), other studies indicate no 
change in SarA protein levels (Horsburgh, 2002) or even a SigB-promoted downregulation of 
sarA (Cheung, 1999). These conflicting observations may potentially arise from either 
technical variables or significant differences in the genetic backgrounds of examined strains. 
In our study, overall sarA transcript levels determined by real-time RT-PCR were increased 
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by <2-fold in rsbU+ -restored strain TE2 compared to RA1 and TE1. Nevertheless, it is 
unlikely that increased sarA transcript levels may account for increased fnbB mRNA levels, in 
particular because sarA was previously established to upregulate fnbA but not fnbB 
transcription (Wolz, 2000; Xiong, 2004).  
Previous studies reported that hla was negatively regulated by σB, and sigB mutants 
expressed higher α-hemolysin activities than their respective wild-type mutants (Cheung, 
1999; Nicholas, 1999; Kullik, 1998). In this study, rsbU+ sigB+ strain TE2 expressed much 
lower hla mRNA level (6% of RA1) and yielded much smaller hemolytic zones on sheep 
blood agar than RA1 and TE1, which is consistent with the previous studies (Bischoff, 2004; 
Cheung, 1999). In contrast, previous studies reported that spa was negatively regulated by 
both sarA and agr at transcriptional (Dunman, 2001) and translational (Chien, 1999) levels. 
The high increase (>25-fold) in spa mRNA level of rsbU+ sigB+ strain TE2 compared to TE1 
and RA1 cannot be explained by the sole contribution of agr and sarA and likely may be due 
to some other unknown regulatory mechanisms. 
In conclusion, these results provide evidence that optimal expression of a stress response 
factor and triggering of a drug-induced DNA repair system may independently, but in an 
additive manner, lead to an impressive >30-fold increase in fnbB transcript levels and promote 
S. aureus attachment to fibronectin. Ongoing studies performed in our laboratory also provide 
preliminary evidence that increased FnBP expression in the SigB-restored strain TE2 grown 
in the presence of ciprofloxacin can upregulate their uptake by non-professional phagocytes 
(Renzoni, unpublished data). Further studies of SigB-regulated pathways using combined 
approaches of transcription profiling, targeted mutagenesis, and functional assays, are 
required to better understand how multiresistant clinical isolates may take benefit of the 
highly flexible regulation of S. aureus colonization and virulence. 
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